<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0705233598
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BRAFTOVI
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENCORAFENIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2252.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT PHARMA SOLUTIONS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT PHARMA SOLUTIONS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Braftovi is an anti-cancer medicine that contains the active substance encorafenib. Changes (mutations) in the BRAF gene can produce proteins that cause the cancer to grow. Braftovi targets proteins made from this changed BRAF gene.</p><p>&nbsp;</p><p>It is used in combination with another medicine containing binimetinib to treat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients with a type of skin cancer called melanoma when it has</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a particular change (mutation) in a gene responsible for producing a protein called BRAF, and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spread to other parts of the body, or cannot be removed by surgery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults with a type of lung cancer called non-small cell lung cancer (NSCLC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that has spread to other parts of the body, <strong>and</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that has a certain type of abnormal &ldquo;BRAF&rdquo; gene</p><p>When Braftovi is used in combination with binimetinib, which targets another protein that stimulates cancer cell growth, the combination slows down or stops the growth of your cancer.</p><p>&nbsp;</p><p>Braftovi is also used in combination with another medicine cetuximab, to treat adult patients with colorectal cancer (cancer of colon or rectum) when it has</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a particular change (mutation) in a gene responsible for producing a protein called BRAF, and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spread to other parts of the body of patients, <strong>and</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; been previously treated with other anticancer medicines</p><p>When Braftovi is used in combination with cetuximab (which binds to the epidermal growth factor receptor (EGFR)), a protein on the surface of certain cancer cells), the combination slows down or stops the growth of your cancer.</p><p>&nbsp;</p><p>BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI is right for you.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before starting treatment your doctor will check for the BRAF mutation.</p><p><em>&nbsp;</em></p><p>As Braftovi is to be used in combination with binimetinib to treat melanoma, read the binimetinib leaflet carefully as well as this leaflet.&nbsp;</p><p><em>&nbsp;</em></p><p>As Braftovi is to be used in combination with cetuximab to treat colorectal cancer, read the cetuximab leaflet carefully as well as this leaflet.&nbsp;</p><p><em>&nbsp;</em></p><p><strong>Do not take Braftovi </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to encorafenib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Braftovi, about all of your medical conditions, particularly if you have any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems including alteration of the electrical activity of your heart (QT interval prolongation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding problems or if you are taking medicines that may cause bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood levels of potassium, calcium, or magnesium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver or kidney problems</p><p>&nbsp;</p><p>Tell your doctor if you have had a different type of cancer than melanoma or colorectal cancer, as Braftovi may worsen certain other types of cancers.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse immediately if you get the following while you are taking this medicine:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart problems:</strong> Braftovi when taken with binimetinib can cause heart problem. Your doctor will check that your heart is working properly before and during your treatment with these medicines. Talk to your doctor immediately if you have any symptoms of heart problems such as feeling dizzy, tired, lightheaded, if you have shortness of breath, if you feel like your heart is pounding, racing, or if you have swelling in the hands, ankles legs or feet.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Changes in the electrical activity of your heart called QT prolongation:</strong> QT prolongation can cause irregular heartbeats that can be life threatening. Your doctor provider should do tests before you start taking BRAFTOVI with binimetinib or cetuximab and during your treatment to check your body salts (electrolytes). Tell your doctor right away if you feel faint, lightheaded, dizzy or if you feel your heart beating irregularly or fast during treatment with BRAFTOVI and binimetinib or cetuximab. These symptoms may be related to QT prolongation.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bleeding problems:</strong> Braftovi may cause serious bleeding problems including in stomach or brain that can lead to death. Talk to your doctor immediately if you have any symptoms of bleeding problems such as coughing up of blood, blood clots, vomit containing blood or that looks like &ldquo;coffee grounds&rdquo;, red or black stools that look like tar, passing blood in the urine, stomach (abdominal) pain, unusual vaginal bleeding. Also tell your doctor if you have headache, dizziness or weakness.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye problems:</strong> Braftovi, when taken with binimetinib, can cause serious eye problems. Talk to your doctor immediately if you get blurred vision, loss of vision, or other vision changes (e.g. coloured dots in your vision), halo (seeing blurred outline around objects). Your doctor will examine your eyes for any problems with your sight while you are taking Braftovi.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin changes:</strong> Braftovi may cause other types of skin cancer such as cutaneous squamous cell carcinoma or basal cell carcinoma. New melanomas may also occur while taking Braftovi. Your doctor will check your skin for any new skin cancers before treatment, every 2&nbsp;months during treatment, and for up to 6 months after you stop taking Braftovi. Tell your doctor immediately if you detect skin changes during and after treatment including: new wart, skin sore or reddish bump that bleeds or does not heal, or a change in size or colour of a mole. Additionally, your doctor needs to check for squamous cell carcinoma on your head, neck, mouth and lymph glands, and you will have CT scans regularly. This is a precaution in case a squamous cell carcinoma develops inside your body.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver problems:</strong> Braftovi can cause abnormal blood tests related to how your liver works (raised levels of liver enzymes). Your doctor will run blood tests to check your liver before and during treatment.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Kidney problems:</strong> Braftovi can alter your kidney activity (often abnormal blood tests, more rarely dehydration and vomiting). Your doctor will run blood tests to monitor your kidneys before and during treatment. Drink plenty of fluids during treatment. Tell your doctor immediately if you vomit and become dehydrated.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Braftovi is not recommended for children and adolescents under 18&nbsp;years of age. This medicine has not been studied in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Braftovi</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may affect how Braftovi works or make it more likely that you will have side effects.</p><p>In particular, tell your doctor if you are taking anything in this list or any other medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat fungal infections (such as itraconazole, posaconazole, fluconazole)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat bacterial infections (such as rifampicin, clarithromycin, telithromycin, erythromycin, penicillin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines typically used to treat epilepsy (seizures) (such as phenytoin, carbamazepine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines typically used to treat cancer (such as methotrexate, imatinib)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines typically used to treat high cholesterol (such as rosuvastatin, atorvastatin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an herbal treatment for depression: St. John&rsquo;s wort</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for HIV treatment such as ritonavir, amprenavir, raltegravir, dolutegravir</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; birth control medicines containing hormones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines typically used to treat high blood pressure (such as diltiazem, bosentan, furosemide)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat an uneven heartbeat: amiodarone.</p><p>&nbsp;</p><p><strong>Braftovi with food and drink </strong></p><p>Do not have grapefruit juice during your treatment with Braftovi. This is because it could increase Braftovi side effects.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><u>Pregnancy</u></p><p>Braftovi is not recommended during pregnancy. It may cause harm or birth defects to an unborn baby.</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>If you are a woman who could become pregnant, you must use reliable contraception<strong> </strong>while you are taking Braftovi, and you must continue to use reliable contraception for 2 weeks after taking your last dose. Birth control medicines containing hormones (such as birth control pills, injections and transdermal systems) that release hormones) may not work as well as expected while you are taking Braftovi. You should use another reliable method of birth control such as a barrier method (e.g. condom) so you do not become pregnant while you are taking this medicine. Ask your doctor, pharmacist or nurse for advice.</p><p>Contact your doctor straightaway if you become pregnant while taking Braftovi.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>It is not known if Braftovi passes into breast milk. &nbsp;Do not breast-feed during treatment with BRAFTOVI and for 2 weeks after taking the last dose of BRAFTOVI. Talk to your doctor about the best way to feed your baby during this time.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Braftovi may reduce sperm count in males. This could affect the ability to father a child. Talk to your doctor if this is a concern for you.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Braftovi can affect your ability to drive or use machines. Avoid driving or using machines if you have any problems with your vision, or have any other side effects that can affect your ability to drive or use machines (see section&nbsp;4), while taking Braftovi. Talk to your doctor if you are not sure you can drive.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take </strong></p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><u>For melanoma and NSCLC treatment</u></p><p>The recommended dose of Braftovi to treat melanoma is 6&nbsp;capsules of 75&nbsp;mg once daily (corresponding to a daily dose of 450&nbsp;mg). You will also receive treatment with another medicine, binimetinib.</p><p>&nbsp;</p><p><u>For </u><u>colorectal </u><u>cancer treatment</u></p><p>The recommended dose of Braftovi to treat colorectal cancer is 4&nbsp;capsules of 75&nbsp;mg once daily (corresponding to a daily dose of 300&nbsp;mg). You will also receive treatment with another medicine cetuximab intravenously.</p><p>&nbsp;</p><p>If you have liver or kidney problems, your doctor may start you on a lower dose.</p><p>If you get serious side effects (such as heart, eye or bleeding problems) your doctor may lower the dose or stop treatment temporarily or permanently.</p><p>&nbsp;</p><p><strong>How to take Braftovi</strong></p><p>Instructions to open the blister:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not push the capsule through the blister.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Separate one blister cell by bending it and gently tearing along the perforations.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carefully peel off the blister foil starting at the corner labelled with an arrow.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently remove the capsule.</p><p><strong>&nbsp;</strong></p><p>Braftovi can be taken with food or between meals.</p><p>&nbsp;</p><p><strong>If you are sick </strong></p><p>If you vomit at any time after taking Braftovi, do not take an additional dose. Take the next dose as scheduled.</p><p>&nbsp;</p><p><strong>If you take more Braftovi than you should</strong></p><p>If you take more capsules than you should, contact your doctor, pharmacist or nurse straightaway. If possible, show them this leaflet and the medicine package.</p><p>&nbsp;</p><p><strong>If you forget to take Braftovi</strong></p><p>If you miss a dose of Braftovi, take it as soon as you remember. However if the missed dose is more than 12&nbsp;hours late, skip that dose and take your next dose at the usual time. Then continue taking your capsules at regular times as usual.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Braftovi</strong></p><p>It is important to take Braftovi for as long as your doctor prescribes it. Do not change your dose or stop taking this medicine unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Braftovi may cause serious side effects. Tell your doctor immediately </strong>if you have any of the following serious side effects, either for the first time or if they get worse (see also section&nbsp;2):</p><p>&nbsp;</p><p><strong>Heart problems:</strong><strong> </strong>Braftovi, when taken with binimetinib can affect how well your heart works (left ventricular ejection fraction decrease); signs and symptoms can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, tired, faint or lightheaded</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling like your heart is pounding, racing or beating irregularly</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the hands, ankles legs or feet</p><p>&nbsp;</p><p><strong>Liver problems</strong>. BRAFTOVI, when taken with binimetinib, can cause liver problems. Your doctor will perform blood tests to check your liver function before and during treatment with BRAFTOVI. Tell your doctor if you get any of the following signs and symptoms of a liver problem:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of your skin or your eyes&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark or brown (tea-colored) urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea or vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding</p><p>&nbsp;</p><p><strong>Eye problems:</strong> Braftovi, when taken with binimetinib can cause serious eye problems. Call your doctor right away if you get these symptoms of eye problems:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, loss of vision, or other vision changes (such as coloured dots in your vision)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; halo (seeing blurred outline around objects)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye pain, swellling or redness</p><p>&nbsp;</p><p><strong>Bleeding problems:</strong> Braftovi can cause serious bleeding problems including in stomach or brain that can lead to death. Tell your doctor right away if you have any unusual signs of bleeding, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headaches, dizziness or weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up of blood or blood clots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomit containing blood or that looks like &ldquo;coffee grounds&rdquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red or black stools that look like tar</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other skin cancers: Treatment with Braftovi may result in a type of skin cancer such as cutaneous squamous cell carcinoma or basal cell carcinoma. Usually, these skin changes (see also section&nbsp;2) are confined to a small area and can be removed with surgery and treatment with Braftovi can continue without interruption. Some people taking Braftovi may also notice new melanomas. These melanomas are usually removed by surgery and treatment with Braftovi can continue without interruption.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Besides the serious side effects mentioned above, people taking Braftovi may also get other side effects.</p><p>&nbsp;</p><p><strong>The most common </strong><strong>side effects when Braftovi and binimetinib are taken together for treatment of melanoma</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or swelling of your joints (arthralgia)</p><p>&nbsp;</p><p><strong>The most common </strong><strong>side effects when Braftovi is taken </strong><strong>together with </strong><strong>cetuximab for treatment of </strong><strong>colorectal </strong><strong>cancer</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne-like rash (dermatitis acneiform)</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach-area (abdominal) pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or swelling of your joints (arthralgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>The most common</strong><strong> side effects when Braftovi is taken </strong><strong>together with </strong><strong>binimetinib for NSCLC </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle or joint pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach-area (abdominal) pain</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, loss of vision, or other vision changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report</strong><strong> side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C. Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is encorafenib.</p><p>Braftovi 50&nbsp;mg:<strong> </strong>Each hard capsule contains 50&nbsp;mg encorafenib.</p><p>Braftovi 75&nbsp;mg:<strong> </strong>Each hard capsule contains 75&nbsp;mg encorafenib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp; Capsule contents: copovidone (E1208), poloxamer 188, cellulose microcrystalline (E460i), succinic acid (E363), crospovidone (E1202), silica colloidal anhydrous (E551), magnesium stearate (E470b)</p><p>&middot;&nbsp;&nbsp;&nbsp; Capsule shell: gelatin (E441), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172)</p><p>&middot;&nbsp;&nbsp;&nbsp; Printing ink: shellac (E904), iron oxide black (E172), propylene glycol (E1520)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Braftovi 50 mg hard capsules 
	The hard capsule (capsule) has an orange opaque cap and flesh opaque body, with a stylised “A” printed on the cap and “LGX 50mg” printed on the body. 
	Braftovi 50 mg is available in pack of 28x1 capsules in polyamide/aluminium/PVC/aluminium/PET/paper perforated unit dose blisters. 
	
	Braftovi 75 mg hard capsules 
	The hard capsule (capsule) has beige cap and white opaque body, with a stylised “A” printed on the cap and “LGX 75mg” printed on the body.
	Braftovi 75 mg is available in pack of 42x1 capsules in polyamide/aluminium/PVC/aluminium/PET/paper perforated unit dose blisters. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Europe MA EEIG</p><p>Boulevard de la Plain 17, 1050 Bruxelles, Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Catalent Pharma Solutions LLC<br />Somerset, NJ 08873, USA<br /><br /><strong>Packaging &amp; Release by</strong></p><p>Pierre Fabre M&eacute;dicament Production Site</p><p>Progipharm, GIEN, France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">برافتوفي هو دواء مضاد للسرطان يحتوي على المادة الفعالة إنكورافينيب. يمكن أن تؤدي التغيرات (الطفرات) في جين BRAF إلى إنتاج بروتينات تتسبب في نمو السرطان. ويستهدف برافتوفي البروتينات الناتجة عن جين BRAF المتغير هذا.</p><p>&nbsp;</p><p dir="RTL">يتم استخدام برافتوفي مع دواء آخر يحتوي على بينيميتينيب لعلاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابين بنوع من سرطان الجلد يسمى الورم الميلانيني عند</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغير (طفرة) معين في الجين المسؤول عن إنتاج بروتين يسمى BRAF،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وانتشار الورم إلى أجزاء أخرى من الجسم، أو في حالة عدم القدرة على إزالته جراحيًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج المرضى البالغين المصابين بنوع من سرطان الرئة يسمى سرطان الرئة ذا الخلايا غير الصغيرة (NSCLC):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذي ينتشر إلى أجزاء أخرى من الجسم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>و</strong> لديه نوع معين غير طبيعي من الجين المسؤول عن إنتاج بروتين &quot;BRAF&quot;</p><p dir="RTL">عند استخدام برافتوفي مع بينيميتينيب، الذي يستهدف بروتينًا آخر يحفز نمو الخلايا السرطانية، يؤدي الجمع بينهما إلى إبطاء نمو السرطان الذي تعاني منه أو إيقافه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم برافتوفي أيضًا مع دواء آخر يسمى سيتوكسيماب لعلاج المرضى البالغين المصابين بسرطان القولون والمستقيم (سرطان القولون أو المستقيم) عند</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغير (طفرة) معين في الجين المسؤول عن إنتاج بروتين يسمى BRAF،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وانتشار السرطان إلى أجزاء أخرى من جسم المرضى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>و</strong>الذين سبق علاجهم باستخدام أدوية أخرى مضادة للسرطان</p><p dir="RTL">عند استخدام برافتوفي مع سيتوكسيماب (الذي يرتبط بمستقبل عامل نمو البشرة (EGFR)، وهو بروتين موجود على سطح بعض الخلايا السرطانية)، يؤدي الجمع بينهما إلى إبطاء نمو السرطان الذي تعاني منه أو إيقافه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي استخدام برافتوفي لعلاج الأشخاص المصابين بالورم الميلانيني الذي تسببه الطفرة الطبيعية لجين BRAF، أو سرطان القولون والمستقيم الذي تسببه الطفرة الطبيعية لجين BRAF، أو سرطان الرئة ذو الخلايا غير الصغيرة الذي تسببه الطفرة الطبيعية لجين BRAF. سيقوم مقدم الرعاية الصحية الخاص بك بإجراء اختبار للتأكد من أن برافتوفي مناسب لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل بدء العلاج، سيفحصك طبيبك للتحقق من وجود طفرة BRAF.</p><p><em>&nbsp;</em></p><p dir="RTL">نظرًا لاستخدام برافتوفي مع بينيميتينيب لعلاج الورم الميلانيني، اقرأ نشرة بينيميتينيب بعناية وكذلك هذه النشرة.&nbsp;</p><p><em>&nbsp;</em></p><p dir="RTL">نظرًا لاستخدام برافتوفي مع سيتوكسيماب لعلاج سرطان القولون والمستقيم، اقرأ نشرة سيتوكسيماب بعناية وكذلك هذه النشرة.&nbsp;</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>موانع استعمال برافتوفي</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إنكورافينيب أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال برافتوفي</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول برافتوفي بشأن جميع حالاتك الطبية، خاصة إذا كنت تعاني من أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في القلب بما في ذلك تغير النشاط الكهربي لقلبك (إطالة فترة QT)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات نزيف أو إذا كنت تتناول أدوية قد تسبب النزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة من البوتاسيوم أو الكالسيوم أو المغنسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكبد أو الكلى</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت مصابًا بنوع مختلف من السرطان بخلاف الورم الميلانيني أو سرطان القولون والمستقيم، نظرًا لأن برافتوفي قد يؤدي إلى تفاقم حالة بعض آخر من أنواع السرطانات.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة فورًا إذا أصبت بما يلي خلال فترة تناول هذا الدواء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات في القلب:</strong> عند تناول برافتوفي مع بينيميتينيب، يمكن أن يتسبب ذلك في حدوث مشكلة في القلب. سيتحقق طبيبك من أن قلبك يعمل بشكل سليم قبل وأثناء علاجك بهذين الدواءين. تحدث إلى طبيبك على الفور إذا كان لديك أي أعراض للإصابة بمشكلات في القلب مثل الشعور بالدوار، أو التعب، أو الدوخة، أو إذا كنت تعاني من ضيق التنفس، أو إذا شعرت بأن قلبك يخفق بشدة أو ضرباته متسارعة، أو إذا كنت تعاني من تورم في اليدين، أو الكاحلين، أو الساقين، أو القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>تغيرات في النشاط الكهربائي للقلب تسمى إطالة فترة </strong><strong>QT</strong><strong>:</strong> يمكن أن تسبب إطالة فترة QT ضربات قلب غير منتظمة يمكن أن تكون مهددة للحياة. يجب على طبيبك إجراء اختبارات قبل أن تبدأ في تناول برافتوفي مع بينيميتينيب أو سيتوكسيماب وأثناء العلاج للتحقق من أملاح الجسم (الإلكتروليتات). أخبر طبيبك على الفور إذا شعرت بالإغماء أو الدوار أو الدوخة أو إذا شعرت أن ضربات قلبك غير منتظمة أو سريعة أثناء العلاج ببرافتوفي مع بينيميتينيب أو سيتوكسيماب. قد تكون هذه الأعراض مرتبطة بإطالة فترة QT.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات نزيف:</strong> قد يسبب برافتوفي مشكلات نزيف خطيرة، بما في ذلك في المعدة أو المخ، يمكن أن تؤدي إلى الوفاة. تحدث إلى طبيبك على الفور إذا كان لديك أي أعراض لمشكلات نزيف مثل السعال المصحوب بخروج الدم، جلطات الدم، القيء الذي يحتوي على دم أو الذي يشبه &quot;ثفل القهوة&quot;، البراز الأحمر أو الأسود الذي يشبه القطران، خروج دم في البول، آلام المعدة (البطن)، النزيف المهبلي غير المعتاد. أخبر طبيبك أيضًا إذا كنت تعاني من الصداع، أو الدوار، أو الضعف.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات في العين:</strong> يمكن أن يسبب برافتوفي، عند تناوله مع بينيميتينيب، مشكلات خطيرة في العين. تحدث إلى طبيبك على الفور إذا كنت تعاني من تغيم الرؤية، أو فقدان الرؤية، أو تغيرات أخرى في الرؤية (مثل وجود نقاط ملونة في مجال رؤيتك)، أو رؤية هالات (رؤية إطار ضبابي حول الأشياء). سيقوم طبيبك بفحص عينيك بحثًا عن أي مشكلات في رؤيتك أثناء تناولك برافتوفي.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تغيرات جلدية:</strong> قد يؤدي برافتوفي إلى الإصابة بنوع آخر من أنواع سرطان الجلد، مثل سرطانة الخلايا الحرشفية الجلدية أو سرطانة الخلايا القاعدية. قد تحدث أيضًا إصابة بأورام ميلانينية جديدة أثناء تناول برافتوفي. سيقوم طبيبك بفحص جلدك بحثًا عن أي سرطانات جلدية جديدة قبل العلاج، وكل شهرين أثناء العلاج، ولمدة تصل إلى ٦ أشهر بعد توقفك عن تناول برافتوفي. أخبر طبيبك على الفور إذا اكتشفت تغيرات جلدية أثناء وبعد العلاج بما في ذلك: الثآليل حديثة الظهور، أو القرح الجلدية، أو النتوءات المائلة للون الأحمر التي تنزف أو لا تُشفى، أو تغير في حجم أو لون شامة. بالإضافة إلى ذلك، يحتاج طبيبك إلى التحقق من إصابتك بسرطانة الخلايا الحرشفية في رأسك، وعنقك، وفمك، وغددك الليمفاوية، وستخضع لفحوصات بالتصوير المقطعي المحوسب (CT) بانتظام. وهذا إجراء احتياطي تحسبًا لظهور سرطانة الخلايا الحرشفية داخل جسمك.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات في الكبد:</strong> يمكن أن يتسبب برافتوفي في نتائج غير طبيعية لفحوصات الدم المتعلقة بكيفية عمل كبدك (ارتفاع مستويات إنزيمات الكبد). سيقوم طبيبك بإجراء فحوصات دم لفحص كبدك قبل وأثناء العلاج.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات في الكلى:</strong> يمكن أن يغير برافتوفي نشاط كليتيك (نتائج غير طبيعية لفحوصات الدم بشكل شائع، الإصابة بالجفاف والقيء في حالات أكثر ندرة). سيقوم طبيبك بإجراء فحوصات دم لمراقبة كليتيك قبل وأثناء العلاج. اشرب الكثير من السوائل أثناء العلاج. أخبر طبيبك على الفور إذا كنت تتقيأ وأُصبت بالجفاف.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يوصى بعدم استخدام برافتوفي لعلاج الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عامًا. لم تتم دراسة هذا الدواء في هذه الفئة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة، إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;قد تؤثر بعض الأدوية على طريقة عمل برافتوفي أو تزيد من احتمالية إصابتك بأعراض جانبية.</p><p dir="RTL">أخبر طبيبك على وجه الخصوص إذا كنت تتناول أيًا من الأشياء المدرجة في هذه القائمة أو أي أدوية أخرى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم لعلاج العدوى الفطرية (مثل إيتراكونازول، بوساكونازول، فلوكونازول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم لعلاج العدوى البكتيرية (مثل ريفامبيسين، كلاريثروميسين، تيليثرومايسين، إريثرومايسين، بنسلين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم عادة لعلاج الصرع (النوبات) (مثل فينيتوين، كاربامازيبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم عادة لعلاج السرطان (مثل ميثوتريكسات، إيماتينيب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم عادة لعلاج ارتفاع مستوى الكولستيرول (مثل روسوفاستاتين، أتورفاستاتين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج عشبي للاكتئاب: نبتة سانت جون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم لعلاج فيروس نقص المناعة البشرية (HIV) مثل ريتونافير، أمبرينافير، رالتجرافير، دولوتجرافير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية منع الحمل التي تحتوي على هرمونات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم عادة لعلاج ضغط الدم المرتفع (مثل ديلتيازيم، بوسنتان، فيوروسيميد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستخدم لعلاج ضربات القلب غير المنتظمة: أميودارون.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول برافتوفي مع الطعام والشراب</strong></p><p dir="RTL">لا تتناول عصير الجريب فروت أثناء علاجك ببرافتوفي. وذلك لأنه يمكن أن يزيد من الأعراض الجانبية لبرافتوفي.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا يوصى بتناول برافتوفي أثناء الحمل. فقد يسبب ضررًا أو عيوبًا ولادية للجنين.</p><p dir="RTL">إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ قبل تناول هذا الدواء.</p><p dir="RTL">إذا كنتِ امرأة قادرة على الإنجاب، يجب عليكِ استخدام وسيلة منع حمل موثوقة أثناء تناولكِ برافتوفي ويجب عليكِ الاستمرار في استخدام وسيلة منع حمل موثوقة لمدة أسبوعين بعد تناول آخر جرعة من الدواء. قد لا تعمل أدوية منع الحمل التي تحتوي على هرمونات (مثل حبوب منع الحمل، والحقن، وأنظمة عبر الجلد التي تطلق الهرمونات) بالكفاءة المتوقعة أثناء تناولكِ برافتوفي. ينبغي أن تستخدمي وسيلة موثوقة أخرى لمنع الحمل، كوسيلة عازلة (مثل الواقي الذكري) حتى لا تصبحين حاملًا خلال فترة تناول هذا الدواء. استشيري طبيبكِ أو الصيدلي أو الممرضة.</p><p dir="RTL">تواصلي مع طبيبكِ فورًا إذا أصبحتِ حاملًا خلال فترة تناول برافتوفي.</p><p>&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا يُعرف ما إذا كان برافتوفي يمر إلى لبن الأم أم لا. &nbsp;لا ترضعي طفلك رضاعة طبيعية أثناء العلاج ببرافتوفي ولمدة أسبوعين بعد تناول الجرعة الأخيرة من برافتوفي. تحدثي إلى طبيبك حول أفضل طريقة لإرضاع طفلك خلال هذه الفترة.</p><p>&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">قد يقلل برافتوفي من تعداد الحيوانات المنوية لدى الذكور. ومن الممكن أن يؤثر هذا على القدرة على الإنجاب. تحدث إلى طبيبك إذا كان ذلك يقلقك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير برافتوفي على القيادة واستخدام الآلات</strong></p><p dir="RTL">من الممكن أن يؤثر برافتوفي على قدرتك على القيادة أو استخدام الآلات. تجنب القيادة أو استخدام الآلات إذا كنت تعاني من أي مشكلات في رؤيتك أو أي أعراض جانبية أخرى يمكنها التأثير على قدرتك على القيادة أو استخدام الآلات (انظر القسم ٤) خلال فترة تناول برافتوفي. تحدث إلى طبيبك إذا لم تكن متأكدًا مما إذا كان يمكنك القيادة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الكمية التي ينبغي تناولها</strong></p><p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL"><u>&nbsp;لعلاج الورم الميلانيني وسرطان الرئة ذي الخلايا غير الصغيرة</u></p><p dir="RTL">تبلغ الجرعة الموصى بها من برافتوفي لعلاج الورم الميلانيني ٦ كبسولات تركيز كل منها ٧٥ ملجم مرة واحدة يوميًا (أي ما يعادل جرعة يومية قدرها ٤٥٠ ملجم). ستتلقى أيضًا علاجًا بدواء آخر، وهو بينيميتينيب.</p><p>&nbsp;</p><p dir="RTL"><u>لعلاج سرطان القولون والمستقيم</u></p><p dir="RTL">تبلغ الجرعة الموصى بها من برافتوفي لعلاج سرطان القولون والمستقيم ٤ كبسولات تركيز كل منها ٧٥ ملجم مرة واحدة يوميًا (أي ما يعادل جرعة يومية قدرها ٣٠٠ ملجم). ستتلقى أيضًا علاجًا بدواء آخر، وهو سيتوكسيماب عن طريق الوريد.</p><p>&nbsp;</p><p dir="RTL">إذا كنت مصابًا بمشكلات في الكبد أو الكلى، فقد يصف لك طبيبك جرعة أقل في البداية.</p><p dir="RTL">&nbsp;إذا أصبت بأعراض جانبية خطيرة (مثل مشكلات القلب، أو العين، أو النزيف)، فقد يقلل طبيبك الجرعة أو يوقف العلاج مؤقتًا أو نهائيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;طريقة استخدام برافتوفي</strong></p><p dir="RTL">تعليمات فتح شريط البليستر:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تدفع الكبسولة لإخراجها من شريط البليستر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افصل وحدة كبسولة من شريط البليستر عن طريق ثنيها وخلعها برفق بطول الخطوط المنثقبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشر رقاقة شريط البليستر المعدنية بحرص بدءًا من الركن المعلم بسهم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج الكبسولة برفق.</p><p><strong>&nbsp;</strong></p><p dir="RTL">يمكن تناول برافتوفي مع الطعام أو بين الوجبات.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أصبت بالقيء</strong></p><p dir="RTL">إذا تقيأت في أي وقت بعد تناول برافتوفي، فلا تتناول جرعة إضافية. تناول الجرعة التالية حسب ما هو مقرر.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من برافتوفي</strong></p><p dir="RTL">إذا تناولت عددًا من الكبسولات أكثر مما ينبغي، فتواصل مع طبيبك أو الصيدلي أو الممرضة فورًا. أرِهم هذه النشرة وعبوة الدواء إن أمكن.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة برافتوفي</strong></p><p dir="RTL">إذا فاتتك إحدى جرعات برافتوفي، فتناولها بمجرد تذكرها. ولكن إذا مر أكثر من ١٢ ساعة على موعد الجرعة الفائتة، فتخط تلك الجرعة وتناول جرعتك التالية في الموعد المعتاد. ثم استمر في تناول كبسولاتك في مواعيد منتظمة كالمعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول برافتوفي</strong></p><p dir="RTL">من المهم تناول برافتوفي طوال الفترة التي يحددها طبيبك. لا تغير جرعتك أو تتوقف عن تناول هذا الدواء إلا إذا أخبرك طبيبك بذلك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد يسبب برافتوفي أعراضًا جانبية خطيرة. أخبر طبيبك فورًا</strong> إذا أصبت بأي من الأعراض الجانبية الخطيرة التالية، سواءً لأول مرة أو إذا تفاقمت (انظر أيضًا القسم ٢):</p><p>&nbsp;</p><p dir="RTL"><strong>مشكلات في القلب:</strong> يمكن أن يؤثر برافتوفي عند تناوله مع بينيميتينيب على كفاءة عمل قلبك (انخفاض الكسر القذفي للبطين الأيسر)؛ ويمكن أن تتضمن العلامات والأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو التعب أو الإغماء أو الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بأن قلبك يخفق بشدة أو ضرباته متسارعة أو ينبض بشكل غير منتظم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو الكاحلين أو الساقين أو القدمين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشكلات في الكبد</strong>: عند تناول برافتوفي مع بينيميتينيب، يمكن أن يسبب ذلك مشكلات في الكبد. سيجري طبيبك فحوصات للدم للتحقق من وظائف الكبد قبل وأثناء العلاج ببرافتوفي. أخبر طبيبك إذا ظهرت عليك أي من العلامات والأعراض التالية لمشكلة في الكبد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو العينين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول داكن أو بني (لون الشاي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان أو قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف</p><p>&nbsp;</p><p dir="RTL"><strong>مشكلات في العين:</strong> يمكن أن يسبب برافتوفي عند تناوله مع بينيميتينيب مشكلات خطيرة في العين. اتصل بطبيبك فورًا إذا أصبت بأعراض مشكلات العين هذه:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيم الرؤية، أو فقدان الرؤية، أو حدوث تغيرات أخرى في الرؤية (مثل ظهور نقاط ملونة في مجال رؤيتك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية هالات (رؤية إطار ضبابي حول الأشياء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، أو تورم، أو احمرار العين</p><p>&nbsp;</p><p dir="RTL"><strong>مشكلات نزيف:</strong> يمكن أن يسبب برافتوفي مشكلات نزيف خطيرة، بما في ذلك في المعدة أو المخ، يمكن أن تؤدي إلى الوفاة. أخبر طبيبك فورًا إذا ظهرت عليك أي علامات غير معتادة للنزيف، بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، أو الدوار، أو الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال المصحوب بخروج دم أو الجلطات الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء الذي يحتوي على دم أو الذي يشبه &quot;ثفل القهوة&quot;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز أحمر أو أسود اللون يشبه القطران</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات الجلد الأخرى: قد يؤدي العلاج ببرافتوفي إلى الإصابة بأحد أنواع سرطان الجلد، مثل سرطانة الخلايا الحرشفية الجلدية أو سرطانة الخلايا القاعدية. وعادة ما تكون هذه التغيرات الجلدية (انظر أيضًا القسم ٢) محصورة في منطقة صغيرة، ويمكن إزالتها جراحيًا والاستمرار في العلاج ببرافتوفي دون توقف. قد يلاحظ أيضًا بعض الأشخاص الذين يتناولون برافتوفي ظهور أورام ميلانينية جديدة. ويتم عادة استئصال هذه الأورام الميلانينية جراحيًا، ويمكن الاستمرار في العلاج ببرافتوفي دون توقف.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">بالإضافة إلى الأعراض الجانبية الخطيرة المذكورة أعلاه، قد يصاب أيضًا الأشخاص الذين يتناولون برافتوفي بأعراض جانبية أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية الأكثر شيوعًا عند استخدام برافتوفي وبينيميتينيب معًا لعلاج الورم الميلانيني</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم في المفاصل (ألم المفاصل)</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا عند أخذ برافتوفي </strong><strong>بالتزامن مع </strong><strong>سيتوكسيماب لعلاج سرطان القولون والمستقيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - ألم في منطقة المعدة (البطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - ألم أو تورم في المفاصل (ألم المفاصل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شبيه بحب الشباب (التهاب الجلد العدّي الشكل)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - طفح جلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا عند أخذ برافتوفي بالتزامن مع بينيميتينيب لعلاج سرطان الرئة ذي الخلايا غير الصغيرة</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات أو المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة المعدة (البطن)</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، أو فقدان الرؤية، أو تغيرات أخرى في الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><ul><li dir="RTL">مركز الاتصال الموحد: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p><u>&nbsp;</u></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;<strong>دول الخليج الأخرى</strong></p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية وشريط البليستر بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية. يُخزن في عبوته الأصلية لحمايته من الرطوبة.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p dir="RTL"><em>&nbsp;</em></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي إنكورافينيب.</p><p dir="RTL">برافتوفي ٥٠ ملجم: تحتوي كل كبسولة صلبة على ٥٠ ملجم من إنكورافينيب.</p><p dir="RTL">برافتوفي ٧٥ ملجم: تحتوي كل كبسولة صلبة على ٧٥ ملجم من إنكورافينيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong>محتويات الكبسولة: كوبوفيدون (E1208)، بولوكسامير ١٨٨، سليولوز دقيق التبلور (E460i)، حمض السكسينيك (E363)، كروسبوفيدون (E1202)، سيليكا غروانية لا مائية (E551)، ستيارات المغنيسيوم (E470b)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong>غلاف الكبسولة: جيلاتين (E441)، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172)، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأسود (E172)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong>حبر الطباعة: صمغ اللك (E904)، أكسيد الحديد الأسود (E172)، بروبيلين جليكول (E1520)</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>كبسولات برافتوفي الصلبة ٥٠ ملجم</u></p><p dir="RTL">الكبسولة الصلبة (الكبسولة) لها غطاء برتقالي غير شفاف وجسم بلون الجلد غير شفاف، وتحمل علامة &quot;A&quot; بتصميم مميز مطبوعة على الغطاء و&quot;LGX 50mg&quot; على جسم الكبسولة.</p><p dir="RTL">يتوفر برافتوفي ٥٠ ملجم في عبوة ٢٨&times;١ كبسولة في شرائط بليستر مثقبة ذات جرعة موحدة من البولي أميد/الألومنيوم/البولي فينيل كلوريد (PVC)/الألومنيوم/البولي إيثيلين تيرفثالات (PET)/الورق.</p><p>&nbsp;</p><p dir="RTL"><u>كبسولات برافتوفي الصلبة ٧٥ ملجم</u></p><p dir="RTL">الكبسولة الصلبة (الكبسولة) لها غطاء بلون بني فاتح اللون وجسم أبيض غير شفاف، وتحمل علامة &quot;A&quot; بتصميم مميز مطبوعة على الغطاء و&quot;LGX&nbsp;75mg&quot; على جسم الكبسولة.</p><p dir="RTL">يتوفر برافتوفي ٧٥ ملجم في عبوة ٤٢&times;١ كبسولة في شرائط بليستر مثقبة ذات جرعة موحدة من البولي أميد/الألومنيوم/البولي فينيل كلوريد/الألومنيوم/البولي إيثيلين تيرفثالات/الورق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">فايزر يوروب إم أي إي إي جي<br />بروكسل، بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة</strong></p><p dir="RTL">كاتالينت فارما سوليوشنز إل إل سي<br />سومرسيت، نيوجيرسي، الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شركة التغليف والفسح النهائي</strong><br />بير فابر ميديسامينت برودكشن<br />موقع بروجيفارم، جين، فرنسا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Braftovi 50 mg hard capsules
Braftovi 75 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The chemical name is methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate. The molecular formula is C22H27ClFN7O4S and the molecular weight is 540 daltons. The chemical structure of encorafenib is shown below:












Encorafenib is a white to almost white powder. In aqueous media, encorafenib is slightly soluble at pH 1, very slightly soluble at pH 2, and insoluble at pH 3 and higher.

Braftovi 50 mg hard capsules
Each hard capsule contains 50 mg of encorafenib.

Braftovi 75 mg hard capsules
Each hard capsule contains 75 mg of encorafenib.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule (capsule).

Braftovi 50 mg hard capsules
Orange opaque cap and flesh opaque body, printed with a stylised “A” on the cap and “LGX 50mg” on the body. The length of the capsule is approximately 22 mm. 

Braftovi 75 mg hard capsules
Beige cap and white opaque body, printed with a stylised “A” on the cap and “LGX 75mg” on the body. The length of the capsule is approximately 23 mm.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma</strong></p><p>BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test (see section 4.2).</p><p>&nbsp;</p><p><strong>BRAF V600E Mutation Positive Metastatic Non Small Cell Lung Cancer (NSCLC)</strong></p><p>BRAFTOVI is indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test (see section 4.2).</p><p>&nbsp;</p><p><strong>BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)</strong></p><p>BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy (see section 4.2).</p><p>&nbsp;</p><p><strong>Limitations</strong><strong> of Use</strong></p><p>BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild‑type BRAF NSCLC (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Patient Selection</u></p><p><u>&nbsp;</u></p><p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma</strong></p><p>Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating BRAFTOVI (see sections 4.4 and 5.1)<em>.</em> Information on FDA-approved tests for the detection of BRAF V600E and V600K mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.</p><p><u>&nbsp;</u></p><p><strong>BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)</strong></p><p>Confirm the presence of a BRAF V600E mutation in tumor specimens prior to initiating BRAFTOVI (see sections 4.4 and 5.1). Information on FDA-approved tests for the detection of BRAF V600E mutations in CRC is available at: http://www.fda.gov/CompanionDiagnostics.</p><p><u>&nbsp;</u></p><p><strong>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</strong></p><p>Confirm the presence of a BRAF V600E mutation in tumor or plasma specimens prior to initiating BRAFTOVI (see sections 4.4 and 5.1). If no mutation is detected in a plasma specimen, test tumor tissue. Information on FDA-approved tests for the detection of BRAF V600E mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><strong>Recommended Dosage for BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma and for BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</strong></p><p>The recommended dosage of braftovi is 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity. Refer to the binimetinib prescribing information for recommended binimetinib dosing information.</p><p>&nbsp;</p><p><strong>Recommended Dosage for BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)</strong></p><p>The recommended dosage of BRAFTOVI is 300 mg (four 75 mg capsules) orally once daily in combination with cetuximab until disease progression or unacceptable toxicity. Refer to the cetuximab prescribing information for recommended cetuximab dosing information.</p><p>&nbsp;</p><p><em>Dose modification</em></p><p><em>&nbsp;</em></p><p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma or BRAF V600E Mutation Positive Metastatic NSCLC</strong></p><p>If binimetinib is withheld, reduce BRAFTOVI to a maximum dose of 300 mg (four 75 mg capsules) once daily until binimetinib is resumed (see section 4.4).</p><p>&nbsp;</p><p>Dose reductions for adverse reactions associated with BRAFTOVI are presented in Table 1.</p><p>&nbsp;</p><p>Table&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Toc482965958'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc482965958'><span lang=EN-GB style='font-size:11.0pt;
mso-ansi-language:EN-GB'> SEQ Table \* ARABIC </span></span><span
style='mso-bookmark:_Toc482965958'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Toc482965958'></span><span style='mso-element:field-end'></span><![endif]-->:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dose Reductions for BRAFTOVI for Adverse Reactions &ndash; Melanoma or NSCLC</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p><strong>Action</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>First Dose Reduction</p></td><td style="vertical-align:top"><p>300 mg (four 75 mg capsules) orally once daily</p></td></tr><tr><td style="vertical-align:top"><p>Second Dose Reduction</p></td><td style="vertical-align:top"><p>225 mg (three 75 mg capsules) orally once daily</p></td></tr><tr><td style="vertical-align:top"><p>Subsequent Modification</p></td><td style="vertical-align:top"><p>Permanently discontinue if unable to tolerate BRAFTOVI 225 mg (three&nbsp;75&nbsp;mg capsules) once daily</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)</strong></p><p>If cetuximab is discontinued, discontinue BRAFTOVI.</p><p>&nbsp;</p><p>Dose reductions for adverse reactions associated with BRAFTOVI are presented in Table&nbsp;2.</p><p><strong>&nbsp;</strong></p><p>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dose Reductions for BRAFTOVI for Adverse Reactions &ndash; CRC</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p><strong>Action</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>First Dose Reduction</p></td><td style="vertical-align:top"><p>225 mg (three 75 mg capsules) orally once daily</p></td></tr><tr><td style="vertical-align:top"><p>Second Dose Reduction</p></td><td style="vertical-align:top"><p>150 mg (two 75 mg capsules) orally once daily</p></td></tr><tr><td style="vertical-align:top"><p>Subsequent Modification</p></td><td style="vertical-align:top"><p>Permanently discontinue if unable to tolerate BRAFTOVI 150 mg (two&nbsp;75&nbsp;mg capsules) once daily</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma, and BRAF V600E Mutation Positive Metastatic Colorectal Cancer (CRC), or BRAF V600E Mutation Positive NSCLC</strong></p><p>Dosage modifications for adverse reactions associated with BRAFTOVI are presented in Table 3.</p><p>&nbsp;</p><p>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dosage Modifications for BRAFTOVI for Adverse Reactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><thead><tr><td style="vertical-align:top"><p>Severity of Adverse Reaction<sup>a</sup></p></td><td style="vertical-align:top"><p>Dose Modification for BRAFTOVI</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>New Primary Malignancies (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Non-Cutaneous RAS Mutation-positive Malignancies</p></td><td style="vertical-align:top"><p>Permanently discontinue BRAFTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiomyopathy (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic congestive heart failure or absolute decrease in LVEF of greater than 20% from baseline that is also below LLN</p></td><td style="vertical-align:top"><p>Reduce BRAFTOVI by one dose level (see section&nbsp;4.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If LVEF improves to at least institutional LLN and absolute decrease to less than or equal to 10% compared to baseline, continue BRAFTOVI at the reduced dose (see section&nbsp;4.2).<em> </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement, withhold BRAFTOVI until improves to at least institutional LLN and absolute decrease to less than or equal to 10% compared to baseline and then resume at the reduced dose or reduce dose an additional dose level.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepatotoxicity (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 2 AST or ALT increased</p></td><td style="vertical-align:top"><p>Maintain BRAFTOVI dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement within 4 weeks, withhold BRAFTOVI until improves to Grade 0-1 or to pretreatment/baseline levels and then resume at same dose.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 AST or ALT increased</p></td><td style="vertical-align:top"><p>See Other Adverse Reactions.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Uveitis </em><em>(see section 4.4) </em></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 1-3</p></td><td style="vertical-align:top"><p>If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold BRAFTOVI for up to 6 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improved, resume at same or reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not improved, permanently discontinue BRAFTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue BRAFTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>QTc Prolongation (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QTcF greater than 500 ms and less than or equal to 60 ms increase from baseline</p></td><td style="vertical-align:top"><p>Withhold BRAFTOVI until QTcF less than or equal to 500 ms. Resume at reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If more than one recurrence, permanently discontinue BRAFTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QTcF greater than 500 ms and greater than 60 ms increase from baseline</p></td><td style="vertical-align:top"><p>Permanently discontinue BRAFTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dermatologic [other than Hand-foot Skin Reaction (HFSR)] (see section 4.8)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 2</p></td><td style="vertical-align:top"><p>If no improvement within 2 weeks, withhold BRAFTOVI until Grade 0‑1. Resume at same dose.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3</p></td><td style="vertical-align:top"><p>Withhold BRAFTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue BRAFTOVI.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Other Adverse Reactions (including Hemorrhage) (see section 4.4) and HFSR (see section 4.8)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade 2 or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First occurrence of any Grade 3</p></td><td style="vertical-align:top"><p>Withhold BRAFTOVI for up to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improves to Grade 0-1 or to pretreatment/baseline level, resume at reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement, permanently discontinue BRAFTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First occurrence of any Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue BRAFTOVI or</p><p>Withhold BRAFTOVI for up to 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If improves to Grade 0-1 or to pretreatment/baseline level, then resume at reduced dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no improvement, permanently discontinue BRAFTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade 3</p></td><td style="vertical-align:top"><p>Consider permanently discontinuing BRAFTOVI.</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue BRAFTOVI.</p></td></tr></tbody></table><p>a. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version&nbsp;4.03</p><p>b. Dose modification of BRAFTOVI when administered with binimetinib or with cetuximab is not recommended for new primary cutaneous malignancies; ocular events other than uveitis, iritis, and iridocyclitis; interstitial lung disease/pneumonitis; creatine phosphokinase (CPK) elevation; rhabdomyolysis; and venous thromboembolism.</p><p><strong><u>&nbsp;</u></strong></p><p>Refer to the binimetinib or cetuximab prescribing information for dose modifications for adverse reactions associated with each product, as appropriate.</p><p>&nbsp;</p><p><strong>Dose Modifications for Coadministration With Strong or Moderate CYP3A4 Inhibitors</strong></p><p>Avoid coadministration of BRAFTOVI with strong or moderate CYP3A4 inhibitors. If coadministration is unavoidable, reduce the BRAFTOVI dose according to the recommendations in Table 4. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the BRAFTOVI dose that was taken prior to initiating the CYP3A4 inhibitor (see sections 4.5 and 5.2)<em>.</em></p><p><em>&nbsp;</em></p><p>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dose Reductions for BRAFTOVI for Coadministration With Strong or Moderate CYP3A4 Inhibitors</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Current Daily Dose<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dose for Coadministration with Moderate CYP3A4 Inhibitor</strong></p></td><td style="vertical-align:top"><p><strong>Dose for Coadministration with Strong CYP3A4 Inhibitor</strong></p></td></tr><tr><td style="vertical-align:top"><p>450 mg</p></td><td style="vertical-align:top"><p>225 mg (three 75 mg capsules)</p></td><td style="vertical-align:top"><p>150 mg (two 75 mg capsules)</p></td></tr><tr><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>150 mg (two 75 mg capsules)</p></td><td style="vertical-align:top"><p>75 mg</p></td></tr><tr><td style="vertical-align:top"><p>225 mg</p></td><td style="vertical-align:top"><p>75 mg</p></td><td style="vertical-align:top"><p>75 mg</p></td></tr><tr><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>75 mg</p></td><td style="vertical-align:top"><p>75 mg<sup>b</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Current daily dose refers to recommended dose of BRAFTOVI based on indication or reductions for adverse reactions based on dosing recommendations in Table 1 (Melanoma) and Table 2 (CRC).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Encorafenib exposure at the 75 mg QD BRAFTOVI dosage when coadministered with a strong CYP3A4 inhibitor is expected to be higher than at the 150 mg QD dosage in the absence of a CYP3A4 inhibitor and similar to exposure at the 225 mg QD dosage in the absence of a CYP3A4 inhibitor. Monitor patients closely for adverse reactions and use clinical judgement when using BRAFTOVI with strong CYP3A4 inhibitors at the 150 mg dose level.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Duration of treatment</em></p><p>Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity.</p><p>&nbsp;</p><p><em>Missed doses</em></p><p>Do not take a missed dose of BRAFTOVI within 12&nbsp;hours of the next dose of BRAFTOVI.</p><p>&nbsp;</p><p><em>Vomiting</em></p><p>Do not take an additional dose if vomiting occurs after BRAFTOVI administration but continue with the next scheduled dose.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly patients</em></p><p>Of the 690 patients with BRAF mutation-positive melanoma who received BRAFTOVI in combination with binimetinib across multiple clinical trials, 20% were aged 65 to 74 years and 8% were aged 75 years and older (see section&nbsp;5.1).</p><p>Of the 216 patients with BRAF V600E mutation-positive metastatic CRC who received BRAFTOVI in combination with cetuximab, 62 (29%) were 65 years of age to up to 75 years of age, while 20 (9%) were 75&nbsp;years of age and over (see &nbsp;section&nbsp;5.1).</p><p>Of the 98 patients with BRAF V600E mutation-positive metastatic NSCLC who received BRAFTOVI with binimetinib, 62 (63%) were 65 years of age and over and 20 (20%) were 75&nbsp;years and over (see section 5.1).</p><p>No overall differences in the safety or effectiveness of BRAFTOVI plus binimetinib or BRAFTOVI plus cetuximab were observed in older patients as compared to younger patients.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>No BRAFTOVI dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh Class A) (see section 5.2). A recommended dosage has not been established in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No BRAFTOVI dosage adjustment is recommended in patients with mild to moderate renal impairment (CLcr 30 to &lt;90&nbsp;mL/min) (see section 5.2). A recommended dosage has not been established in patients with severe renal impairment (CLcr &lt;30 mL/min).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and effectiveness of BRAFTOVI have not been established in pediatric patients.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u><br />&nbsp;</p><p>Braftovi is for oral use. BRAFTOVI may be taken with or without food. The concomitant administration of encorafenib with grapefruit juice should be avoided (see sections 4.5 and 5.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>New primary malignancies</u></p><p>&nbsp;</p><p>New primary malignancies, cutaneous and non-cutaneous, have been observed in patients treated with BRAF inhibitors and can occur with BRAFTOVI.</p><p><em>&nbsp;</em></p><p><em>Cutaneous malignancies</em></p><p>In COLUMBUS, cutaneous squamous cell carcinoma (cuSCC), including keratoacanthoma (KA), occurred in 2.6%, and basal cell carcinoma occurred in 1.6% of patients who received BRAFTOVI in combination with binimetinib. Median time to first occurrence of cuSCC/KA was 5.8 months (range 1 to 9 months) (see&nbsp;section 4.8)<em>.</em></p><p>For patients who received BRAFTOVI as a single agent, cuSCC/KA was reported in 8%, basal cell carcinoma in 1%, and a new primary melanoma in 5% of patients.</p><p>In BEACON CRC, cuSCC/KA occurred in 1.4% of patients with CRC, and a new primary melanoma occurred in 1.4% of patients who received BRAFTOVI in combination with cetuximab.</p><p>In PHAROS, cuSCC and skin papilloma, each occurred in 2% of patients who received BRAFTOVI in combination with binimetinib.</p><p>Perform dermatologic evaluations prior to initiating treatment, every 2 months during treatment, and for up to 6 months following discontinuation of treatment. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Dose modification is not recommended for new primary cutaneous malignancies.</p><p>&nbsp;</p><p><em>Non-cutaneous malignancies</em><br />Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms (see section 4.4). Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies (see section 4.2).</p><p>&nbsp;</p><p><u>Tumor Promotion in BRAF Wild-Type Tumors</u></p><p>&nbsp;</p><p>In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells, which are exposed to BRAF inhibitors. Confirm evidence of BRAF V600E or V600K mutation prior to initiating BRAFTOVI (see sections 4.1 and 4.2).</p><p>&nbsp;</p><p><u>Cardiomyopathy</u></p><p>&nbsp;</p><p>Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with BRAFTOVI in combination with binimetinib. In COLUMBUS, evidence of cardiomyopathy (decreased in LVEF below the institutional LLN with an absolute decreased in LVEF &ge;10% below baseline as detected by echocardiography or MUGA) occurred in 7% of patients receiving BRAFTOVI plus binimetinib. Grade 3 left ventricular dysfunction occurred in 1.6% of patients. The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving BRAFTOVI in combination with binimetinib was 3.6 months (range 0 to 21 months). Cardiomyopathy resolved in 87% of patients receiving BRAFTOVI plus binimetinib.</p><p>In PHAROS, evidence of cardiomyopathy (decrease in LVEF below the institutional LLN with an absolute decrease in LVEF &ge;10% below baseline as detected by echocardiography or MUGA) occurred in 11% of patients receiving BRAFTOVI in combination with binimetinib. Grade 3 left ventricular dysfunction occurred in 1% of patients. Cardiomyopathy resolved in 82% of patients receiving BRAFTOVI plus binimetinib.</p><p>Assess ejection fraction by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and every 2 to 3 months during treatment. The safety of BRAFTOVI in combination with binimetinib has not been established in patients with baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely when treated with BRAFTOVI.</p><p>Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see sections 4.2 and<em> </em>4.8).</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>Hepatotoxicity can occur when BRAFTOVI is administered in combination with binimetinib. In COLUMBUS, the incidence of Grade 3 or 4 increases in liver function laboratory tests in patients receiving BRAFTOVI in combination with binimetinib was 6% for alanine aminotransferase (ALT), 2.6% for aspartate aminotransferase (AST), and 0.5% for alkaline phosphatase. In PHAROS, the incidence of Grade 3 or 4 increases in liver function laboratory tests in patients receiving BRAFTOVI in combination with binimetinib was 10% for AST, 9% for ALT, and 3.2% for alkaline phosphatase.</p><p>Monitor liver laboratory tests before initiation of BRAFTOVI, monthly during treatment, and as clinically indicated. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><u>Haemorrhage</u></p><p><u>&nbsp;</u></p><p>In COLUMBUS, hemorrhage occurred in 19% of patients receiving BRAFTOVI in combination with binimetinib; Grade 3 or greater hemorrhage occurred in 3.2% of patients. The most frequent hemorrhagic events were gastrointestinal, including rectal hemorrhage (4.2%), hematochezia (3.1%), and hemorrhoidal hemorrhage (1%). Fatal intracranial hemorrhage in the setting of new or progressive brain metastases occurred in 1.6% of patients.</p><p>In BEACON CRC, hemorrhage occurred in 19% of patients receiving BRAFTOVI in combination with cetuximab; Grade 3 or higher hemorrhage occurred in 1.9% of patients, including fatal gastrointestinal hemorrhage in 0.5% of patients. The most frequent hemorrhagic events were epistaxis (6.9%), hematochezia&nbsp; (2.3%), and rectal hemorrhage (2.3%).</p><p>In PHAROS, hemorrhage occurred in 12% of patients receiving BRAFTOVI in combination with binimetinib including fatal hemorrhage intracranial (1%); Grade 3 or 4 hemorrhage occurred in 4.1% of patients. The most frequent hemorrhagic events were anal hemorrhage and hemothorax (2% each).</p><p>Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see sections 4.2 and 4.8).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Uveitis</u></p><p><u>&nbsp;</u></p><p>Uveitis, including iritis and iridocyclitis, has been reported in patients treated with BRAFTOVI in combination with binimetinib. In COLUMBUS, the incidence of uveitis among patients treated with BRAFTOVI in combination with binimetinib was 4%. In PHAROS, the incidence of uveitis among patients treated with BRAFTOVI in combination with binimetinib was 1%.</p><p>Assess for visual symptoms at each visit. Perform an ophthalmologic evaluation at regular intervals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p><u>&nbsp;</u></p><p>BRAFTOVI is associated with dose-dependent QTc interval prolongation in some patients (see section 5.2). In COLUMBUS, an increase in QTcF to &gt;500 ms was measured in 0.5% (1/192) of patients who received BRAFTOVI in combination with binimetinib. In PHAROS, an increase in QTcF to &gt;500 ms was measured in 2.1% (2/95) of patients who received BRAFTOVI in combination with binimetinib.</p><p>Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during BRAFTOVI administration. Withhold, reduce dose, or permanently discontinue for QTc &gt;500 ms (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>Embryo-Fetal Toxicity</u></p><p>&nbsp;</p><p>Based on its mechanism of action, BRAFTOVI can cause fetal harm when administered to a pregnant woman. Encorafenib produced embryo-fetal developmental changes in rats and rabbits and was an abortifacient in rabbits at doses greater than or equal to those resulting in exposures approximately 26 (in the rat) and 178 (in the rabbit) times the human exposure at the recommended dose of 450 mg, with no clear findings at lower doses.</p><p>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use an effective, non-hormonal method of contraception since BRAFTOVI can render hormonal contraceptives ineffective, during treatment and for 2 weeks after the last dose of BRAFTOVI (see sections 4.6).</p><p>&nbsp;</p><p><u>Risks Associated with BRAFTOVI as a Single Agent</u></p><p>&nbsp;</p><p>BRAFTOVI when used as a single agent is associated with an increased risk of certain adverse reactions compared to when BRAFTOVI is used in combination with binimetinib. In COLUMBUS, Grades 3 or 4 dermatologic reactions occurred in 21% of patients treated with BRAFTOVI single agent compared to 2% of patients treated with BRAFTOVI in combination with binimetinib (see sections 4.4 and 4.8).</p><p>If binimetinib is temporarily interrupted or permanently discontinued, reduce the dose of BRAFTOVI as recommended (see section 4.2).</p><p>&nbsp;</p><p><u>Risks Associated with Combination Treatment</u></p><p>&nbsp;</p><p>BRAFTOVI is indicated for use as part of a regimen in combination with binimetinib or cetuximab. Refer to the prescribing information for binimetinib and cetuximab for additional risk information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on BRAFTOVI</u></p><p><strong>&nbsp;</strong></p><p><em>Strong or Moderate CYP3A4 Inhibitors</em></p><p>Coadministration of BRAFTOVI with a strong or moderate CYP3A4 inhibitor increases encorafenib plasma concentrations (see section 5.2) and may increase encorafenib adverse reactions. Avoid coadministration of BRAFTOVI with strong or moderate CYP3A4 inhibitors, including grapefruit juice. If coadministration is unavoidable, reduce the BRAFTOVI dose (see section 4.2).</p><p>&nbsp;</p><p><em>Strong CYP3A4 Inducers</em></p><p>Coadministration of BRAFTOVI with a strong or moderate CYP3A4 inducer may decrease encorafenib plasma concentrations (see section 5.2) and may decrease encorafenib efficacy. Avoid coadministration of BRAFTOVI with strong or moderate CYP3A4 inducers.</p><p>&nbsp;</p><p><u>Effects of BRAFTOVI on other medicinal products</u></p><p><u>&nbsp;</u></p><p><em>Sensitive CYP3A4 substrates</em></p><p>BRAFTOVI is a strong CYP3A4 inducer at steady-state. Concomitant use of BRAFTOVI may decrease the plasma concentrations of CYP3A4 substrates (including hormonal contraceptives), (see section 5.2), which may reduce the efficacy of these substrates. Avoid the coadministration of BRAFTOVI with CYP3A4 substrates for which a decrease in plasma concentration may lead to reduced efficacy of the substrate. If the coadministration cannot be avoided, see the CYP3A4 substrate product labeling for recommendations.</p><p>&nbsp;</p><p><em>OATP1B1, OATP1B3, or BCRP substrates</em></p><p>Coadministration of BRAFTOVI with OATP1B1, OATP1B3, or BCRP substrates can result in increased concentrations of the substrates, and may increase toxicity of these agents. When used in combination, monitor patients closely for signs and symptoms of increased exposure and consider adjusting the dose of these substrates (see section<em> </em>5.2).</p><p>&nbsp;</p><p><u>Drugs That Prolong the QT Interval</u></p><p>&nbsp;</p><p>BRAFTOVI is associated with dose-dependent QTc interval prolongation (see sections 4.4 and 5.2). Avoid coadministration of BRAFTOVI with drugs known to prolong the QT/QTc interval.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in females </u></p><p><u>&nbsp;</u></p><p>BRAFTOVI can cause fetal harm when administered to a pregnant woman.</p><p>&nbsp;</p><p><em>Pregnancy Testing</em></p><p>Verify the pregnancy status of females of reproductive potential prior to initiating BRAFTOVI.</p><p><em>&nbsp;</em></p><p><em>Contraception</em></p><p>Advise females of reproductive potential to use effective contraception during treatment with BRAFTOVI and for 2 weeks after the last dose. Counsel patients to use a non-hormonal method of contraception since BRAFTOVI has the potential to render hormonal contraceptives ineffective (see section 4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p><em>Risk Summary</em></p><p>Based on its mechanism of action, BRAFTOVI can cause fetal harm when administered to a pregnant woman (see section 5.2). There are no available clinical data on the use of BRAFTOVI during pregnancy. In animal reproduction studies, encorafenib produced embryo-fetal developmental changes in rats and rabbits and was an abortifacient in rabbits at doses greater than or equal to those resulting in exposures approximately 26 (in the rat) and 178 (in the rabbit) times the human exposure at the clinical dose of 450 mg, with no clear findings at lower doses (see Data). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p><strong>&nbsp;</strong></p><p><strong>Data</strong></p><p><em>Animal Data</em></p><p>In reproductive toxicity studies, administration of encorafenib to rats during the period of organogenesis resulted in maternal toxicity, decreased fetal weights, and increased incidence of total skeletal variations at a dose of 20 mg/kg/day (approximately 26 times the human exposure based on area under the concentration-time curve [AUC] at the recommended clinical dose of 450 mg once daily). In pregnant rabbits, administration of encorafenib during the period of organogenesis resulted in maternal toxicity, decreased fetal body weights, increased incidence of total skeletal variations and increased post-implantation loss, including total loss of pregnancy at a dose of 75 mg/kg/day (approximately 178 times the human exposure based on AUC at the recommended clinical dose of 450 mg once daily). While formal placental transfer studies have not been performed, encorafenib exposure in the fetal plasma of both rats and rabbits was up to 1.7% and 0.8%, respectively, of maternal exposure.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p><em>Risk Summary</em></p><p>There are no data on the presence of encorafenib or its metabolites in human milk or the effects of encorafenib on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child from BRAFTOVI, advise women not to breastfeed during treatment with BRAFTOVI and for 2 weeks after the last dose.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Based on findings in male rats at doses approximately 13 times the human exposure at the 450 mg clinical dose, use of BRAFTOVI may impact fertility in males &nbsp;(see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Encorafenib has minor influence on the ability to drive or use machines. Visual disturbances have been reported in some patients treated with encorafenib during clinical studies. Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reactions that may affect their ability to drive and use machines (see sections&nbsp;4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are described elsewhere in the labeling:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New Primary Malignancies (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor Promotion in BRAF Wild-Type Tumors (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhage (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uveitis (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QT Prolongation (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Embryo-Fetal Toxicity (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risks Associated with BRAFTOVI as a Single Agent (see section&nbsp;4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risks Associated with Combination Treatment (see section&nbsp;4.4)</p><p>&nbsp;</p><p>Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p><u>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma</u></p><p>The safety of BRAFTOVI in combination with binimetinib is described in 192 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma who received BRAFTOVI (450 mg once daily) in combination with binimetinib (45 mg twice daily) in a randomized open-label, active-controlled trial (COLUMBUS).</p><p>The COLUMBUS trial (see section&nbsp;5.1) excluded patients with a history of Gilbert&rsquo;s syndrome, abnormal left ventricular ejection fraction, prolonged QTc (&gt;480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 11.8 months for patients treated with BRAFTOVI in combination with binimetinib and 6.2 months for patients treated with vemurafenib.</p><p>The most common (&gt;25%) adverse reactions in patients receiving BRAFTOVI in combination with binimetinib were fatigue, nausea, vomiting, abdominal pain, and arthralgia.</p><p>Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 30% of patients receiving BRAFTOVI in combination with binimetinib; the most common were nausea (7%), vomiting (7%), and pyrexia&nbsp;(4%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 14% of patients receiving BRAFTOVI in combination with binimetinib; the most common were arthralgia (2%), fatigue (2%), and nausea&nbsp;(2%). Five percent (5%) of patients receiving BRAFTOVI in combination with binimetinib experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI; the most common were hemorrhage in 2% and headache in 1% of patients.</p><p>Table 5 and Table 6 present adverse drug reactions and laboratory abnormalities, respectively, identified in COLUMBUS. The COLUMBUS trial was not designed to demonstrate a statistically significant difference in adverse reaction rates for BRAFTOVI in combination with binimetinib, as compared to vemurafenib, for any specific adverse reaction listed in Table 5.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="5"><p><strong>Table&nbsp;5</strong><strong>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Occurring in &ge;10% of Patients Receiving BRAFTOVI in Combination With Binimetinib in COLUMBUS<sup>a</sup></strong></p></td></tr><tr><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="2"><p><strong>BRAFTOVI</strong></p><p><strong>with binimetinib</strong></p><p><strong>N=192</strong></p></td><td colspan="2"><p><strong>Vemurafenib</strong></p><p><strong>N=186</strong></p></td></tr><tr><td><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grades</strong></p><p><strong>3 and 4<sup>b</sup></strong></p><p><strong>(%)</strong></p></td><td><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grades</strong></p><p><strong>3 and 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia<sup>c</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting<sup>c</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain<sup>c</sup></p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia<sup>c</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myopathy<sup>c</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in extremity</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperkeratosis<sup>c</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash<sup>c</sup></p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin<sup>c</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia<sup>c</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus<sup>c</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache<sup>c</sup></p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness<sup>c</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral neuropathy<sup>c</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhage<sup>c</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Grade 4 adverse reactions limited to fatigue (n=1), pruritus (n=1), and rash (n=1) in the BRAFTOVI with binimetinib arm.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; Represents a composite of multiple, related preferred terms.</p><p>&nbsp;</p><p>BRAFTOVI when used as a single agent increases the risk of certain adverse reactions compared to BRAFTOVI in combination with binimetinib. In patients receiving BRAFTOVI 300 mg orally once daily as a single agent, the following adverse reactions were observed at a higher rate (&ge;5%) compared to patients receiving BRAFTOVI in combination with binimetinib: palmar-plantar erythrodysesthesia syndrome (51%&nbsp;vs. 7%), hyperkeratosis (57% vs. 23%), dry skin (38% vs. 16%), erythema (16% vs. 7%), rash (41% vs. 22%), alopecia (56% vs. 14%), pruritus (31% vs. 13%), arthralgia (44% vs. 26%), myopathy (33% vs. 23%), back pain (15% vs. 9%), dysgeusia (13% vs. 6%), and acneiform dermatitis (8% vs. 3%).</p><p>Other clinically important adverse reactions occurring in &lt;10% of patients who received BRAFTOVI in combination with binimetinib were:</p><p>Nervous system disorders: <em>Facial paresis</em></p><p>Gastrointestinal disorders: <em>Pancreatitis</em></p><p>Skin and subcutaneous tissue disorders:<em> Panniculitis, Photosensitivity</em></p><p>Immune system disorders:<em> Drug hypersensitivity</em></p><p>&nbsp;</p><p>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp; Laboratory Abnormalities Occurring in &ge;10% (All Grades) of Patients Receiving BRAFTOVI in Combination With Binimetinib in COLUMBUS<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p><p>Laboratory Abnormality</p></td><td colspan="2"><p>BRAFTOVI</p><p>with binimetinib<sup>a</sup></p><p>N=192</p></td><td colspan="2"><p>Vemurafenib<sup>a</sup></p><p>N=186</p></td></tr><tr><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4</p><p>(%)</p></td><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades</p><p>3 and 4</p><p>(%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Anemia</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Leukopenia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Lymphopenia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Neutropenia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Creatinine</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>92</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Gamma Glutamyl Transferase</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased ALT</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased AST</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hyperglycemia</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Increased Alkaline Phosphatase</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hyponatremia</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypermagnesemia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.5</p></td></tr></tbody></table><p>a. Grades per National Cancer Institute CTCAE v4.03.</p><p><u>&nbsp;</u></p><p><u>BRAF</u><u> V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)</u></p><p>The safety of BRAFTOVI 300 mg once daily in combination with cetuximab (400 mg/m<sup>2</sup> initial dose, followed by 250 mg/m<sup>2</sup> weekly) was evaluated in 216 patients with BRAF V600E mutation-positive metastatic CRC in a randomized, open-label, active-controlled trial (BEACON CRC). The BEACON CRC trial (see section&nbsp;5.1) excluded patients with a history of Gilbert&rsquo;s syndrome, abnormal left ventricular ejection fraction, prolonged QTc (&gt;480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 4.4 months for patients treated with BRAFTOVI in combination with cetuximab and 1.6 months for patients treated with either irinotecan or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI) in combination with cetuximab.</p><p>The most common (&ge;25%) adverse reactions in patients receiving BRAFTOVI in combination with cetuximab were fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, and rash.</p><p>Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 33% of patients receiving BRAFTOVI in combination with cetuximab; the most common were vomiting (4%), fatigue (4%), nausea (4%), pyrexia (3%), and diarrhea (3%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 9% of patients receiving BRAFTOVI in combination with cetuximab; the most common were fatigue (2%), arthralgia (2%), and peripheral neuropathy (2%). Ten percent (10%) of patients receiving BRAFTOVI in combination with cetuximab experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI. None of the adverse reactions leading to permanent discontinuation of BRAFTOVI occurred in more than one patient (&gt;0.5%).</p><p>Table&nbsp;7 and Table&nbsp;8 present adverse drug reactions and laboratory abnormalities, respectively, identified in BEACON CRC.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="7"><p><strong>Table&nbsp;7</strong><strong>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Occurring in &ge;10% of Patients Receiving BRAFTOVI in Combination With Cetuximab in BEACON CRC</strong><sup>a</sup></p></td></tr><tr><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="3"><p><strong>BRAFTOVI</strong></p><p><strong>with cetuximab</strong></p><p><strong>N=216</strong></p></td><td colspan="3"><p><strong>Irinotecan with cetuximab or FOLFIRI with cetuximab</strong></p><p><strong>N=193</strong></p></td></tr><tr><td colspan="2"><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>&ge; Grade 3<sup>b</sup></strong></p><p><strong>(%)</strong></p></td><td colspan="2"><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>&ge; Grade 3</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>50</p></td><td colspan="2" style="vertical-align:top"><p>8</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pyrexia<sup>c</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>15</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>41</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Diarrhea<sup>c</sup></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>48</p></td><td colspan="2" style="vertical-align:top"><p>10</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abdominal pain<sup>c</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>32</p></td><td colspan="2" style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>29</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>18</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>27</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Arthralgia<sup>c</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Myopathy<sup>c</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dermatitis acneiform<sup>c</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>43</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rash<sup>c</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>26</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pruritus<sup>c</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Melanocytic nevus</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dry skin<sup>c</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Headache<sup>c</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Peripheral neuropathy<sup>c</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>6</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hemorrhage<sup>c</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>9</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Insomnia<sup>c</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Grade 4-5 adverse reactions in the BRAFTOVI with cetuximab arm were limited to Grade 5 hemorrhage (n=1).</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; Represents a composite of multiple, related preferred terms.</p><p>&nbsp;</p><p>Other clinically important adverse reactions occurring in &lt;10% of patients who received BRAFTOVI in combination with cetuximab were:</p><p>Gastrointestinal disorders: <em>Pancreatitis</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><thead><tr><td colspan="5"><p><strong>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory Abnormalities Occurring in &ge;10% (All Grades) of Patients Receiving BRAFTOVI in Combination With Cetuximab in BEACON CRC<sup>a</sup></strong></p></td></tr><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Laboratory Abnormality<sup>b</sup></strong></p></td><td colspan="2"><p><strong>BRAFTOVI</strong></p><p><strong>with cetuximab</strong></p></td><td colspan="2"><p><strong>Irinotecan with cetuximab or FOLFIRI with cetuximab</strong></p></td></tr><tr><td><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grades</strong></p><p><strong>3 and 4</strong></p><p><strong>(%)</strong></p></td><td><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grades</strong></p><p><strong>3 and 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Hematology</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td><p>34</p></td><td><p>4</p></td><td><p>48</p></td><td><p>5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lymphopenia</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Increased Activated Partial Thromboplastin Time</p></td><td><p>13</p></td><td><p>1</p></td><td><p>7</p></td><td><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Chemistry</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypomagnesemia</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased Alkaline Phosphatase</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased ALT</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased AST</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalemia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatremia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the number of patients with available baseline and at least one on-treatment laboratory test.</p><p><u>&nbsp;</u></p><p><u>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</u></p><p>The safety of BRAFTOVI in combination with binimetinib was evaluated in 98 patients with BRAF V600E mutation-positive metastatic NSCLC who received BRAFTOVI (450 mg once daily) in combination with binimetinib (45 mg twice daily) in an open-label, single-arm trial (PHAROS).</p><p>The PHAROS trial (see<em> </em>section 5.1) excluded patients with abnormal left ventricular ejection fraction, prolonged QTc (&gt;480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of treatment for BRAFTOVI and binimetinib was 9.2 and 8.4&nbsp;months, respectively.</p><p>The most common (&ge;25%) adverse reactions in patients receiving BRAFTOVI were fatigue, nausea, diarrhea, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough.</p><p>Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 59% of patients receiving BRAFTOVI; the most common (&ge;5%) were diarrhea (17%); nausea (13%); musculoskeletal pain, fatigue (8% each); AST increased (7%); ALT increased, anemia, hemorrhage, vomiting (6% each); and acute kidney injury&nbsp;(5%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 30% of patients receiving BRAFTOVI; the most common (&ge;5%) were diarrhea, nausea (8% each); AST increased and fatigue (5% each). A total of 16% of patients receiving BRAFTOVI experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI; the most common (&ge;2%) were diarrhea, musculoskeletal pain (3.1% each); fatigue, rash, nausea, visual impairment, and vomiting (2% each). None of the other adverse reactions leading to permanent discontinuation of BRAFTOVI occurred in more than 1 patient.</p><p>Serious adverse reactions occurred in 38% of patients who received BRAFTOVI in combination with binimetinib. Serious adverse reactions occurring in &ge;2% of patients were hemorrhage (6%); diarrhea (4.1%); anemia, dyspnea, pneumonia (3.1% each); arrhythmia, device related infection, edema, myocardial infarction, and pleural effusion (2% each). Fatal adverse reactions occurred in 2% of patients who received BRAFTOVI (450 mg once daily) in combination with binimetinib, including intracranial hemorrhage and myocardial infarction (1% each).</p><p>Table 9 and Table 10 present adverse drug reactions and laboratory abnormalities, respectively, identified in PHAROS.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><thead><tr><td colspan="3"><p>Table 9:&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Occurring in &ge;10% of Patients Receiving BRAFTOVI in Combination with Binimetinib in PHAROS<sup>a</sup></p></td></tr><tr><td rowspan="2"><p>Adverse Reaction</p></td><td colspan="2"><p>BRAFTOVI</p><p>with binimetinib<br />N=98</p></td></tr><tr><td><p>All</p><p>Grades</p><p>(%)</p></td><td><p>Grades 3 and 4<sup>b</sup></p><p>(%)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Edema<sup>d</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>3.1</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea<sup>e</sup></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>f</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment<sup>g</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>h</sup></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>4.1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>i</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>3.1</p></td></tr><tr><td style="vertical-align:top"><p>Pruritis<sup>j</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>k</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>l</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness<sup>m</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>b,n</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>4.1</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Left ventricular dysfunction/cardiomyopathy<sup>o</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One Grade 5 adverse reaction of hemorrhage occurred.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue includes fatigue, asthenia.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edema includes edema peripheral, generalized edema, swelling, localized edema, face edema.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea includes diarrhea, colitis.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, epigastric discomfort.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual impairment includes vision blurred, visual impairment, vitreous floaters, photophobia, visual acuity reduced, photopsia.</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal pain includes back pain, arthralgia, pain in extremity, myalgia, musculoskeletal chest pain, non-cardiac chest pain, neck pain.</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash includes rash, rash macular, rash maculo-papular, rash papular, rash pustular, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, eczema, skin exfoliation.</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritis includes pruritus, pruritus genital.</p><p>k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnea includes dyspnea, dyspnea exertional.</p><p>l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough includes cough, productive cough.</p><p>m.&nbsp;&nbsp;&nbsp;&nbsp; Dizziness includes dizziness, balance disorder.</p><p>n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhage includes anal hemorrhage, hemothorax, gastrointestinal hemorrhage, hematochezia, hematuria, hemoptysis, hemorrhage intracranial, hyphema, small intestinal hemorrhage, upper gastrointestinal hemorrhage, vaginal hemorrhage.</p><p>o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Left ventricular dysfunction/cardiomyopathy includes ejection fraction decreased, cardiac failure, cardiac failure congestive.</p></td></tr></tbody></table><p>Other clinically important adverse reactions occurring in &lt;10% of patients who received BRAFTOVI in combination with binimetinib were:</p><p>Nervous system disorders: <em>Peripheral neuropathy, Dysgeusia,</em> <em>Facial paresis</em></p><p>Gastrointestinal disorders: <em>Pancreatitis</em></p><p>Skin and subcutaneous tissue disorders: <em>Hyperkeratosis, Erythema, Photosensitivity</em></p><p>Immune system disorders:<em> Drug hypersensitivity</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><thead><tr><td colspan="3"><p><strong>Table&nbsp;10:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory Abnormalities Occurring in &ge;10% (All Grades) of Patients Receiving BRAFTOVI with Binimetinib<sup>a</sup> </strong></p></td></tr><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Laboratory Abnormality<sup>b</sup></strong></p></td><td colspan="2"><p><strong>BRAFTOVI with binimetinib</strong></p></td></tr><tr><td><p><strong>All</strong></p><p><strong>Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grades</strong></p><p><strong>3 and 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Hematology</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td><p>47</p></td><td><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td><p>12</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td><p>12</p></td><td><p>1.1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Chemistry</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased creatinine</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Increased creatine kinase</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Increased ALT</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminemia</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Increased AST</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Increased alkaline phosphatase</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalemia</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatremia</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Serum amylase increased</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>2.1</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grades per National Cancer Institute CTCAE v4.03.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the number of patients with available baseline and at least one on-treatment laboratory test.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:360px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since encorafenib is 86% bound to plasma proteins, hemodialysis is likely to be ineffective in the treatment of overdose with BRAFTOVI.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01EC03</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in&nbsp;vitro cell-free assays with IC<sub>50</sub> values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Encorafenib was also able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36 and reduce ligand binding to these kinases at clinically achievable concentrations (&le;0.9&nbsp;&micro;M).</p><p>Encorafenib inhibited in vitro growth of tumor cell lines expressing BRAF V600 E, D, and K mutations. In mice implanted with tumor cells expressing BRAF V600E<em>,</em> encorafenib induced tumor regressions associated with RAF/MEK/ERK pathway suppression.</p><p>Encorafenib and binimetinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared with either drug alone, coadministration of encorafenib and binimetinib resulted in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. Additionally, the combination of encorafenib and binimetinib delayed the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared to either drug alone. In a BRAF V600E mutant NSCLC patient-derived xenograft model in mice, coadministration of encorafenib and binimetinib resulted in greater anti-tumor activity compared to binimetinib alone, with respect to tumor growth inhibition. Increased tumor growth delay after dosing cessation was also observed with the coadmnistration compared to either drug alone.</p><p>In the setting of BRAF-mutant CRC, induction of EGFR-mediated MAPK pathway activation has been identified as a mechanism of resistance to BRAF inhibitors. Combinations of a BRAF inhibitor and agents targeting EGFR have been shown to overcome this resistance mechanism in nonclinical models. Coadministration of encorafenib and cetuximab had an anti-tumor effect greater than either drug alone, in a mouse model of colorectal cancer with mutated BRAF V600E.</p><p>&nbsp;</p><p><em><u>Cardiac Electrophysiology</u></em></p><p>A dedicated study to evaluate the QT prolongation potential of BRAFTOVI has not been conducted. BRAFTOVI is associated with dose-dependent QTc interval prolongation. Based on a central tendency analysis of QTc in a study of adult patients with melanoma who received the recommended dose of BRAFTOVI in combination with binimetinib, the largest mean (90%&nbsp;CI) QTcF change from baseline (&Delta;QTcF) was 18&nbsp;(14&nbsp;to&nbsp;22) ms (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>&nbsp;</em></p><p><strong>BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma</strong></p><p>BRAFTOVI in combination with binimetinib was evaluated in a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453). Eligible patients were required to have BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as detected using the bioMerieux THxID&trade;BRAF assay. Patients were permitted to have received immunotherapy in the adjuvant setting and one prior line of immunotherapy for unresectable locally advanced or metastatic disease. Prior use of BRAF inhibitors or MEK inhibitors was prohibited. Randomization was stratified by American Joint Committee on Cancer (AJCC) Stage (IIIB, IIIC, IVM1a or IVM1b, versus IVM1c), Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1), and prior immunotherapy for unresectable or metastatic disease (yes versus no).</p><p>Patients were randomized (1:1:1) to receive BRAFTOVI 450 mg once daily in combination with binimetinib 45&nbsp;mg twice daily (BRAFTOVI in combination with binimetinib), BRAFTOVI 300&nbsp;mg once daily, or vemurafenib 960 mg twice daily. Treatment continued until disease progression or unacceptable toxicity. Only the results of the approved dosing (BRAFTOVI 450 mg in combination with binimetinib 45 mg) are described below.</p><p>The major efficacy outcome measure was progression-free survival (PFS), as assessed by a blinded independent central review, to compare BRAFTOVI in combination with binimetinib with vemurafenib. Additional efficacy outcome measures included overall survival (OS), as well as objective response rate (ORR) and duration of response (DoR) which were assessed by central review.</p><p>A total of 577 patients were randomized, 192 to the BRAFTOVI in combination with binimetinib arm, 194&nbsp;to the BRAFTOVI arm, and 191 to the vemurafenib arm. Of the 383 patients randomized to either the BRAFTOVI in combination with binimetinib or the vemurafenib arms, the median age was 56 years (20 to 89&nbsp;years), 59%&nbsp;were male, 91% were White, and 72% had baseline ECOG performance status of 0. Ninety‑five percent (95%) had metastatic disease, 65% were Stage IVM1c, and 4% received prior CTLA-4, PD-1, or PD-L1 directed antibodies. Twenty-eight percent (28%) had elevated baseline serum lactate dehydrogenase (LDH), 45% had &ge;3 organs with tumor involvement at baseline, and 3% had brain metastases. Based on centralized testing, 100% of patients&rsquo; tumors tested positive for BRAF mutations; BRAF V600E (88%), BRAF V600K&nbsp;(11%), or both (&lt;1%).</p><p>BRAFTOVI in combination with binimetinib demonstrated a statistically significant improvement in PFS compared to vemurafenib. Efficacy results are summarized in Table&nbsp;11 and Figure&nbsp;1.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;</strong><strong>11</strong><strong>:&nbsp;&nbsp; Efficacy Results for COLUMBUS</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p>&nbsp;</p></td><td colspan="3"><p>BRAFTOVI</p><p>with binimetinib</p><p>N=192</p></td><td><p>Vemurafenib</p><p>N=191</p></td></tr></thead><tbody><tr><td colspan="5"><p>Progression-Free Survival</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Number of events (%)</p></td><td colspan="3" style="vertical-align:top"><p>98 (51)</p></td><td style="vertical-align:top"><p>106 (55)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Progressive disease</p></td><td colspan="3" style="vertical-align:top"><p>88 (46)</p></td><td style="vertical-align:top"><p>104 (54)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Death</p></td><td colspan="3" style="vertical-align:top"><p>10 (5)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median PFS, months (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>14.9 (11.0, 18.5)</p></td><td style="vertical-align:top"><p>7.3 (5.6, 8.2)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; HR (95% CI)<sup>a</sup></p></td><td colspan="4" style="vertical-align:top"><p>0.54 (0.41, 0.71)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; <em>P</em>-value<sup>b</sup></p></td><td colspan="4" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="5"><p>Overall Survival<sup>c</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Number of events (%)</p></td><td style="vertical-align:top"><p>139 (72)</p></td><td colspan="2" style="vertical-align:top"><p>147 (77)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median OS, months (95% CI)</p></td><td style="vertical-align:top"><p>33.6 (24.4, 39.2)</p></td><td colspan="2" style="vertical-align:top"><p>16.9 (14.0, 24.5)</p></td></tr><tr><td colspan="2"><p>&nbsp;&nbsp;&nbsp; HR (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.67 (0.53, 0.84)</p></td></tr><tr><td colspan="5"><p>Overall Response Rate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; ORR (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>63% (56%, 70%)</p></td><td style="vertical-align:top"><p>40% (33%, 48%)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; CR</p></td><td colspan="3" style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; PR</p></td><td colspan="3" style="vertical-align:top"><p>55%</p></td><td style="vertical-align:top"><p>35%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Duration of Response</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median DoR, months (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>16.6 (12.2, 20.4)</p></td><td style="vertical-align:top"><p>12.3 (6.9, 16.9)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>CI = Confidence interval; CR = Complete response; DoR = Duration of response; HR = Hazard ratio; NE = Not estimable; ORR = Overall response rate; OS = Overall survival; PFS = Progression-free survival; PR = Partial response.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Estimated with Cox proportional hazard model adjusted by the following stratification factors: American Joint Committee on Cancer (AJCC) Stage (IIIB, IIIC, IVM1a or IVM1b, versus IVM1c) and Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Log-rank test adjusted by the same stratification factors.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp; Based on a cutoff date of 82.4 months after the date of the PFS analysis.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1</strong><strong>:&nbsp;&nbsp; Kaplan-Meier Curves for Progression-Free Survival in COLUMBUS</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)</p><p>&nbsp;</p><p>BRAFTOVI in combination with cetuximab was evaluated in a randomized, active-controlled, open-label, multicenter trial (BEACON CRC; NCT02928224). Eligible patients were required to have BRAF V600E mutation-positive metastatic colorectal cancer (CRC), as detected using the Qiagen therascreen BRAF V600E RGQ polymerase chain reaction (PCR) Kit, with disease progression after 1 or 2 prior regimens. Other key eligibility criteria included absence of prior treatment with a RAF, MEK, or EGFR inhibitor, eligibility to receive cetuximab per local labeling with respect to tumor RAS status, and ECOG performance status (PS) 0-1. Randomization was stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0&nbsp;versus&nbsp;1), prior use of irinotecan (yes versus no), and cetuximab product used (US‑licensed versus EU-approved).</p><p>Patients were randomized 1:1:1 to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BRAFTOVI 300 mg orally once daily in combination with cetuximab (BRAFTOVI/cetuximab arm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BRAFTOVI 300 mg orally once daily in combination with binimetinib and cetuximab</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irinotecan with cetuximab or FOLFIRI with cetuximab (control arm)</p><p>The dosage of cetuximab in all patients was 400 mg/m<sup>2</sup> intravenously for the first dose followed by 250&nbsp;mg/m<sup>2</sup> weekly.</p><p>Patients in the control arm received cetuximab with either irinotecan 180 mg/m<sup>2</sup> intravenously on Days 1 and&nbsp;15 of each 28‑day cycle or FOLFIRI intravenously (irinotecan 180 mg/m<sup>2</sup> on Days 1 and 15; folinic acid 400 mg/m<sup>2</sup> on Days 1 and 15; then fluorouracil 400 mg/m<sup>2</sup> bolus on Days 1 and 15 followed by fluorouracil 2400 mg/m<sup>2</sup>/day by continuous infusion over 2 days).</p><p>Treatment continued until disease progression or unacceptable toxicity. Only the results of the approved regimen (BRAFTOVI in combination with cetuximab) are described below.</p><p>The major efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures included progression-free survival (PFS), overall response rate (ORR), and duration of response (DoR) as assessed by blinded independent central review (BICR). OS and PFS were assessed in all randomized patients. ORR and DoR were assessed in the subset of the first 220 patients included in the randomized portion of the BRAFTOVI/cetuximab and control arm of the study.</p><p>A total of 220 patients were randomized to the BRAFTOVI/cetuximab arm and 221 to the control arm. Of these 441 patients, the median age was 61 years; 53% were female; 80% were White and 15% were Asian. Fifty percent (50%) had baseline ECOG performance status of 0; 66% received 1 prior therapy and 34% received 2; 93% received prior oxaliplatin and 52% received prior irinotecan. &nbsp;</p><p>BRAFTOVI in combination with cetuximab demonstrated a statistically significant improvement in OS, ORR, and PFS compared to the active comparator. Efficacy results are summarized in Table&nbsp;12 and Figure&nbsp;2.</p><p>&nbsp;</p><p><strong>Table&nbsp;12:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results From BEACON CRC</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>BRAFTOVI with cetuximab</strong></p><p><strong>N = 220</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Irinotecan with cetuximab or FOLFIRI with cetuximab</strong></p><p><strong>N = 221</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of Events (%)</p></td><td style="vertical-align:top"><p>93 (42)</p></td><td style="vertical-align:top"><p>114 (52)</p></td></tr><tr><td style="vertical-align:top"><p>Median OS, months (95% CI)</p></td><td style="vertical-align:top"><p>8.4 (7.5, 11.0)</p></td><td style="vertical-align:top"><p>5.4 (4.8, 6.6)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>a,b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.60 (0.45, 0.79)</p></td></tr><tr><td style="vertical-align:top"><p><em>P</em>-value<sup>a,c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0003</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall Response Rate (per BICR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR (95% CI)<sup>d</sup></p></td><td style="vertical-align:top"><p>20% (13%, 29%)</p></td><td style="vertical-align:top"><p>2% (0%, 7%)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p><em>P</em>-value<sup>a,e</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Median DoR, months (95% CI)</p></td><td style="vertical-align:top"><p>6.1 (4.1, 8.3)</p></td><td style="vertical-align:top"><p>NR (2.6, NR)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression Free Survival (per BICR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>133 (60)</p></td><td style="vertical-align:top"><p>128 (58)</p></td></tr><tr><td style="vertical-align:top"><p>Progressive disease</p></td><td style="vertical-align:top"><p>110 (50)</p></td><td style="vertical-align:top"><p>101 (46)</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>23 (10)</p></td><td style="vertical-align:top"><p>27 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS, months (95% CI)</p></td><td style="vertical-align:top"><p>4.2 (3.7, 5.4)</p></td><td style="vertical-align:top"><p>1.5 (1.4, 1.7)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>a,b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.40 (0.31, 0.52)</p></td></tr><tr><td style="vertical-align:top"><p><em>P</em>-value<sup>a,f</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>CI = Confidence interval; CR = Complete response; DoR = Duration of response; HR = Hazard ratio; NR = Not reached; ORR = Overall response rate; OS = Overall survival; PFS = Progression-free survival; PR = Partial response.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stratified by ECOG PS, source of cetuximab (US-licensed versus EU-approved) and prior irinotecan use at randomization.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stratified Cox proportional hazard model.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stratified log-rank test, tested at alpha level of 0.0084.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BRAFTOVI/cetuximab arm (n=113) and control arm (n=107).</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cochran-Mantel-Haenszel test; tested at alpha level of 0.05.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stratified log-rank test, tested at alpha level of 0.0234.</p><p>&nbsp;</p><p><strong>Figure&nbsp;2</strong><strong>:&nbsp;&nbsp; Kaplan-Meier Curves for Overall Survival in BEACON CRC</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer</p><p>BRAFTOVI in combination with binimetinib was evaluated in an open-label, multicenter, single‑arm study in patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC) (PHAROS; NCT03915951). Eligible patients had a diagnosis of histologically-confirmed metastatic NSCLC with BRAF V600E mutation that was treatment-na&iuml;ve or had been previously treated with 1 prior line of systemic therapy in the metastatic setting (platinum-based chemotherapy and/or anti-PD-1/PD-L1 therapies), age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, and measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Prior use of BRAF inhibitors or MEK inhibitors was not allowed.</p><p>Patients received BRAFTOVI 450 mg once daily and binimetinib 45 mg orally twice daily until disease progression or unacceptable toxicity. The major efficacy outcome measures were objective response rate (ORR) per RECIST v1.1 and duration of response (DoR) as assessed by independent review committee (IRC).</p><p>In the efficacy population, BRAF V600E mutation status was determined by prospective local testing using tumor tissue (78%) or blood (22%) specimens. Of the 98 patients with BRAF V600E mutation, 6 patients were enrolled into the trial based on testing of their tumor tissue specimens with the FoundationOne CDx tissue test. Of the remaining 92 patients enrolled based on local testing, 68 patients had their tumor tissue specimens retrospectively confirmed as having BRAF V600E positive status by the FoundationOne CDx tissue test. The remaining patients had either BRAF V600E negative status (n=5) or had unevaluable results (n=19) by the FoundationOne CDx tissue test. In addition, plasma samples from 81 out of 98 patients were retrospectively tested using the FoundationOne Liquid CDx assay. Of the 81 patients, 48 were confirmed positive for BRAF V600E, while 33 patients were BRAF V600E mutation negative by FoundationOne Liquid CDx assay. The remaining 17 samples had unevaluable results with FoundationOne Liquid CDx assay.</p><p>The efficacy population included 59&nbsp;treatment-na&iuml;ve patients and 39 previously-treated patients. Among these 98 patients, the median age was 70 years (range: 47&nbsp;to 86); 53% female; 88% White, 7% Asian, 3% Black or African American, and 1% American Indian or Alaska Native; 99% were not Hispanic or Latino; 13% were current smokers and 57% were former smokers; 73% had ECOG PS of 1; and 97% had adenocarcinoma. All patients had metastatic disease, and 8% had brain metastases at baseline.</p><p>Efficacy results for patients with BRAF V600E mutation-positive metastatic NSCLC are summarized in Table&nbsp;13.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;13:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results for PHAROS</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAFTOVI with binimetinib</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Treatment na&iuml;ve<br />(N=59)</strong></p></td><td style="vertical-align:top"><p><strong>Previously treated<br />(N=39)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Objective Response Rate<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR (95% CI)</p></td><td style="vertical-align:top"><p>75% (62, 85)</p></td><td style="vertical-align:top"><p>46% (30, 63)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>59%</p></td><td style="vertical-align:top"><p>36%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>N=44</p></td><td style="vertical-align:top"><p>N=18</p></td></tr><tr><td style="vertical-align:top"><p>Median DoR, months (95% CI)</p></td><td style="vertical-align:top"><p>NE (23.1, NE)</p></td><td style="vertical-align:top"><p>16.7 (7.4, NE)</p></td></tr><tr><td style="vertical-align:top"><p>% with DoR &ge;6 months</p></td><td style="vertical-align:top"><p>75%</p></td><td style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>% with DoR &ge;12 months</p></td><td style="vertical-align:top"><p>59%</p></td><td style="vertical-align:top"><p>33%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI = Confidence interval; CR = Complete response; DoR = Duration of response; N = Number of patients; NE = Not estimable; ORR = Objective response rate; PR = Partial response.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by Independent Central Review (ICR).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of encorafenib were studied in healthy subjects and patients with solid tumors, including advanced and unresectable or metastatic cutaneous melanoma harboring a BRAF V600E or V600K mutation, BRAF V600E mutation-positive metastatic CRC. After a single dose, systemic exposure of encorafenib was dose proportional over the dose range of 50 mg to 700 mg (0.1 to 1.6 times the maximum recommended dose of 450 mg). After once-daily dosing, systemic exposure of encorafenib was less than dose proportional over the dose range of 50 mg to 800 mg (0.1 to 1.8 times the maximum recommended dose of 450 mg). Steady-state was reached within 15 days, with exposure being 50% lower compared to Day 1; intersubject variability (CV%) of AUC ranged from 12% to 69%.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>The median T<sub>max</sub> of encorafenib is 2 hours. At least 86% of the dose is absorbed.</p><p><em>&nbsp;</em></p><p><em>Effect of Food</em></p><p>Following administration of a single dose of BRAFTOVI 100 mg (0.2 times the maximum recommended dose of 450&nbsp;mg) with a high-fat, high-calorie meal (consisting of approximately 150 calories from protein, 350 calories from carbohydrates, and 500&nbsp;calories from fat) the mean maximum encorafenib concentration (C<sub>max</sub>) decreased by 36% and there was no effect on AUC.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The geometric mean (CV%) of apparent volume of distribution is 164 L (70%). The protein binding of encorafenib is 86% in vitro. The blood-to-plasma concentration ratio is 0.58.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The mean (CV%) terminal half-life (t<sub>1/2</sub>) of encorafenib is 3.5 hours (17%), and the apparent clearance is 14&nbsp;L/h&nbsp;(54%) at day 1, increasing to 32 L/h (59%) at steady-state at the maximum recommended dose of 450&nbsp;mg.</p><p><em>&nbsp;</em></p><p><em>Metabolism</em></p><p>Encorafenib is primarily metabolized by CYP3A4 (83%) and to a lesser extent by CYP2C19 (16%) and CYP2D6 (1%).</p><p><em>&nbsp;</em></p><p><em>Excretion</em></p><p>Following a single radiolabeled dose of 100 mg encorafenib, 47% (5% unchanged) of the administered dose was recovered in feces and 47% (2% unchanged) in urine.</p><p>&nbsp;</p><p><u>Medicinal product interactions</u></p><p>&nbsp;</p><p><em>Clinical Studies</em></p><p><em>&nbsp;</em></p><p><em>CYP3A4 Inhibitors:</em> Coadministration of posaconazole (strong CYP3A4 inhibitor) or diltiazem (moderate CYP3A4 inhibitor) increased AUC of encorafenib by 3- and 2-fold, respectively, and increased C<sub>max</sub> by 68% and 45%, respectively, after a single dose of 50&nbsp;mg BRAFTOVI (0.1 times the maximum recommended dose of 450&nbsp;mg).</p><p><em>&nbsp;</em></p><p><em>Strong CYP3A4 Inducers:</em> The effect of a strong CYP3A4 inducer on encorafenib exposure has not been studied (see section&nbsp;4.5).</p><p><em>Moderate CYP3A4 Inducers:</em> Repeat dose administration of BRAFTOVI 450 mg once daily and binimetinib 45&nbsp;mg twice daily with modafinil, a moderate CYP3A4 inducer, decreased encorafenib steady-state AUC by 24% and C<sub>max</sub> by 20%, compared to BRAFTOVI alone.</p><p><em>&nbsp;</em></p><p><em>Effect of encorafenib on CYP3A4 Substrates: </em>Repeat dose administration of BRAFTOVI 450 mg once daily and binimetinib 45&nbsp;mg twice daily with a single dose of midazolam 2 mg, a sensitive CYP3A4 substrate, decreased midazolam AUC by 82% and C<sub>max</sub> by 74% relative to midazolam 2 mg alone.</p><p><em>&nbsp;</em></p><p><em>Effect of encorafenib on Other CYP Substrates: </em>There was no clinically significant effect of repeat dose administration of BRAFTOVI 450 mg once daily and binimetinib 45&nbsp;mg twice daily on the exposure of substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP2D6.</p><p><em>Proton Pump Inhibitors: </em>No clinically significant differences in encorafenib pharmacokinetics were observed when coadministered with rabeprazole.</p><p><em>&nbsp;</em></p><p><em>Binimetinib:</em> No clinically significant differences in the pharmacokinetics of binimetinib (UGT1A1&nbsp;substrate) were observed when coadministered with BRAFTOVI (UGT1A1 inhibitor).</p><p><em>Cetuximab: </em>No clinically significant differences in the pharmacokinetics of encorafenib or cetuximab were observed when the recommended BRAFTOVI dose of 300 mg was coadministered with cetuximab.<em> </em></p><p><em>&nbsp;</em></p><p><em>Transporters: </em>Repeat dose administration of BRAFTOVI 450 mg once daily and binimetinib 45 mg twice daily with a single dose of rosuvastatin (a sensitive <em>substrate for </em>OATP1B1, OATP1B3, and BCRP) increased rosuvastatin C<sub>max</sub> by 2.7-fold and AUC by 1.6-fold<em>. </em></p><p><em>&nbsp;</em></p><p><em>In Vitro Studies</em></p><p><em>&nbsp;</em></p><p><em>CYP/UGT Enzymes: </em>Encorafenib is a reversible inhibitor of UGT1A1.</p><p><em>&nbsp;</em></p><p><em>Transporters: </em>Encorafenib is a substrate of P-glycoprotein (P-gp) but not of breast cancer resistance protein (BCRP), multidrug resistance-associated protein 2&nbsp;(MRP2), organic anion transporting polypeptide (OATP1B1, OATP1B3) or organic cation transporter (OCT1) at clinically relevant plasma concentrations.</p><p>&nbsp;</p><p>Encorafenib is an inhibitor of P-gp, BCRP, OCT2, organic anion transporter (OAT1, OAT3), OATP1B1, and OATP1B3, but not of OCT1 or MRP2 at clinically relevant plasma concentrations.</p><p><strong>&nbsp;</strong></p><p><u>Special populations</u></p><p>&nbsp;</p><p>No clinically significant differences in the pharmacokinetics of encorafenib were observed based on age (19&nbsp;to&nbsp;94 years), sex, body weight (34 to 168 kg), mild hepatic impairment (Child-Pugh Class A), and mild or moderate renal impairment (CLcr 30 to &lt;90 mL/min). The effect of race or ethnicity, moderate or severe hepatic impairment (Child-Pugh Class B or C), and severe renal impairment (CLcr &lt;30 mL/min) on encorafenib pharmacokinetics have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>Carcinogenicity studies with encorafenib have not been conducted. Encorafenib was not genotoxic in studies evaluating reverse mutations in bacteria, chromosomal aberrations in mammalian cells, or micronuclei in bone marrow of rats.</p><p>No dedicated fertility studies were performed with encorafenib in animals. In a general toxicology study in rats, decreased testes and epididymis weights, tubular degeneration in testes, and oligospermia in epididymides were observed at doses approximately 13 times the human exposure at the 450 mg clinical dose based on AUC. No effects on reproductive organs were observed in either sex in any of the non-human primate toxicity studies.</p><p>&nbsp;</p><p>Animal Toxicology and/or Pharmacology</p><p>Adverse histopathology findings of hyperplasia and hyperkeratosis occurred in the stomach of rats at encorafenib doses of 20 mg/kg/day (approximately 14 times the human exposure at the 450 mg clinical dose based on AUC) or greater, in both 4 and 13-week studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>&nbsp;</p><p>Copovidone (E1208)</p><p>Poloxamer 188</p><p>Cellulose microcrystalline (E460i)</p><p>Succinic acid (E363)</p><p>Crospovidone (E1202)</p><p>Silica colloidal anhydrous (E551)</p><p>Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p><u>&nbsp;</u></p><p>Gelatin (E441)</p><p>Titanium dioxide (E171)</p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>Iron oxide black (E172)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>&nbsp;</p><p>Shellac (E904)</p><p>Iron oxide black (E172)</p><p>Propylene glycol (E1520)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Braftovi 50&nbsp;mg hard capsules</u></p><p>&nbsp;</p><p>Each pack contains 28x1&nbsp;hard capsules in polyamide/aluminium/PVC/aluminium/ PET/paper perforated unit dose blisters.</p><p>&nbsp;</p><p><u>Braftovi 75&nbsp;mg hard capsules</u></p><p><u>&nbsp;</u></p><p>Each pack contains 42x1&nbsp;hard capsules in polyamide/aluminium/PVC/aluminium/ PET/paper perforated unit dose blisters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Europe MA EEIG 
Boulevard de la Plain 17, 1050 Bruxelles, Belgium

MANUFACTURER
Catalent Pharma Solutions LLC
Somerset, NJ 08873, USA

PACKAGING & RELEASE BY
Pierre Fabre Médicament Production Site
Progipharm, GIEN, France

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2024

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>